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ABSTRACT
Although a number of add-on treatment strategies have been studied to improve the 
outcome of antipsychotic-treated chronic schizophrenia, none of them have thus far 
proved to be conclusively effective. Mirtazapine, an antidepressant with a unique 
receptor profile, improves the clinical effect of first generation antipsychotics (FGAs), in 
terms of negative and extrapyramidal symptoms (EPS) in some published studies, when 
used in conjunction with FGAs. The present study aimed to explore the efficacy of 
adjunctive mirtazapine on the symptoms of schizophrenia in patients with an 
insufficient response to different FGA monotherapies at adequate stable dosages. 
Thirtynine patients who met the DSM-IV-TR criteria for schizophrenia or 
schizoaffective disorder depressive type, and who were at least moderately ill (as 
measured by the Clinical Global Impression Scale) despite their FGA treatment, 
received add-on mirtazapine 30 mg/day (n=20) or placebo (n=19) in a 6-week double-
blind randomized controlled trial (RCT). Thirtyseven completers of the double-blind 
phase were treated in an open-label design with mirtazapine 30 mg/day during an 
additional 6 weeks. Dosages of current antipsychotics remained unchanged. The 
Positive and Negative Syndrome Scale (PANSS) total score (primary outcome), as well 
as secondary outcomes, which included PANSS subscales, Simpson-Angus Scale for 
Extrapyramidal Side-effects (SAS) and Calgary Depression Scale for Schizophrenia 
(CDSS) were measured prospectively. Patients underwent a physical examination 
(weight, vital signs) and a range of laboratory measures that included fasting glucose 
and total cholesterol. Within group and between group differences were compared on 
the Modified Intent-to-Treat basis with Last Observations Carried Forward. Correlation 
analyses and regression analyses were used to measure relationships between clinical 
and metabolic parameters.
In the within group analyses, mirtazapine add-on treatment led to a statistically 
significant improvement of all measured clinical parameters during the double-blind 
phase. Improvement in PANSS total scores was as large as 12.5% (p<0.001), whereas 
the improvement in PANSS positive symptoms was 17.2% (p<0.001) while the 
improvement in PANSS negative symptoms was 12.0% (p<0.001). SAS scores improved 
by 9.8% (p=0.017) and CDSS scores improved by 52% (p=0.003). The latter change 
exhibited a direct correlation with several subscales of PANSS. In the mirtazapine 
group, the effect size was 1.00 (95%CI 0.34-1.67) on the primary outcome parameter. 
The between-group difference favoured mirtazapine on PANSS total scores (p=0.004), 
PANSS positive subscale (p=0.001) and PANSS negative subscale (p=0.001). No 
significant differences were found in other parameters. Mirtazapine treatment led to an 
increase in body weight and cholesterol levels, and the latter change was associated with 
a clinical improvement on all PANSS subscales, where an increase in total cholesterol by 
1 mmol/L predicted a reduction on the PANSS total score by 7 points [r=0.85, p=0.001].
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During the open-label phase, patients who switched to mirtazapine demonstrated an 
improvement in PANSS (effect size 0.94 on PANSS total scores), CDSS and SAS scores 
in a manner similar to their mirtazapine-treated counterparts in the double-blind phase. 
The incidence of adverse events did not differ between mirtazapine and placebo.
These findings indicate that add-on mirtazapine to current FGA treatment is 
significantly more efficacious in the reduction of positive, negative and depressive 
symptoms than a placebo add-on. This is the first RCT report of a statistically significant 
additive antipsychotic effect from an adjunctive antidepressant. Mirtazapine induced 
changes in body weight and lipid metabolism were similar to those seem with the most 
effective antipsychotics, and this metabolic effect may even contribute to its clinical 
efficacy.
The main limitation of the study was its small sample size. Thus, larger and longer 
follow up trials are undoubtedly needed to confirm these results. Further research 
should also consider combinations of mirtazapine with second generation 
antipsychotics, and especially comparisons with clozapine.
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1 INTRODUCTION
Schizophrenia is a serious psychiatric disease that affects approximately 0.5-0.9% of the 
world population (Tandon et al., 2008), and causes considerable suffering to the 
individual, the individual’s family and an enormous economic burden to society 
(Csernansky and Schuchart, 2002). Antipsychotic drugs currently remain the 
cornerstone for the pharmacological treatment of schizophrenia (Leucht et al., 2012). All 
antipsychotics are antagonists of dopamine D2 receptors (Butcher, 2000). Atypical 
antipsychotics (e.g., clozapine and a group of novel compounds) demonstrate higher 
efficacy against negative symptoms, a lower incidence of extrapyramidal side effects, 
improved outcome and a better quality of life (Meltzer, 2012). These advantages of 
atypical antipsychotics over conventional antipsychotics have been often attributed to 
their high affinity to postsynaptic serotonin 5HT2a receptors and a relatively low affinity 
to dopamine D2 receptors, in contrast to conventional antipsychotics, whose D2 affinity 
is high (Meltzer, 1994). Some antidepressants, such as trazodone, mianserine, 
nefazodone and mirtazapine are also potent inhibitors of postsynaptic 5HT2a receptors. 
They are, however, lacking noteworthy D2 receptor affinity and, thus, antipsychotic 
efficacy. Combinations of these antidepressants with conventional antipsychotics could 
result in the atypical-like receptor blockade with additional antidepressive effects and, 
hereby, improvement the negative, depressive, and quality of life domains in 
schizophrenia, with better tolerance.
Preliminary support to this assumption was indicated by several published studies, 
where the addition of 5HT2a-blocking antidepressants to ongoing therapy with first-
generation antipsychotics (FGAs) reduced negative symptoms of schizophrenia (Decina 
et al., 1994, Hayashi et al., 1997). Such antidepressants also improved the antipsychotic-
induced extrapyramidal symptoms (Hayashi et al., 1997, Wynchank and Berk, 2003). 
In addition to 5HT2a receptor blockade, mirtazapine demonstrates inhibitory effects 
at alpha-2 and 5HT3 receptors, as well as indirect agonism at serotonin 5HT1 receptors 
(Berendsen and Broekkamp, 1997). Moreover, these receptors appear to be involved in 
the schizophrenic process (Hertel et al., 1999, Meltzer and Huang, 2008) and 
participate in the mechanism of action of clozapine, which is the most efficacious 
antipsychotic (Asenjo-Lobos et al., 2010). Indeed, in some preclinical studies adjunctive 
mirtazapine enhanced the antipsychotic-like effects and tolerability of conventional 
drugs in an atypical fashion (Berendsen et al., 1998, Pinder et al., 1998). In a previous 
randomized controlled trial (RCT), adjunctive mirtazapine appeared to be superior to 
placebo in terms of improving negative symptoms in haloperidol-treated schizophrenic 
patients (Berk et al., 2001).
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2 REVIEW OF LITERATURE
2.1 SCHIZOPHRENIA.
2.1.1 DEFINITION AND EPIDEMIOLOGY.
Schizophrenia is a serious mental disorder affecting about 24 million people worldwide 
(World Health Organization, 2009). It is among the top ten leading causes of disease-
related disability in the world (Tandon et al., 2008). Due to an early age of onset, and a 
subsequent tendency to persist chronically, schizophrenia generates great suffering for 
patients and causes significant social and economical burdens. A comprehensive survey 
estimated that schizophrenia is responsible for 1.1% of the total disability adjusted life 
years worldwide, and for 2.8% of the years lived with disability worldwide (Jablenski, 
2000).
According to systematic reviews, the incidence of schizophrenia is approximately 
15.2/100000, with a prevalence of approximately 7.2/1000 (McGrath et al., 2004, Saha 
et al., 2005). The incidence of schizophrenia has long been estimated to be relatively 
similar worldwide. However, recent epidemiological studies revealed a considerable 
heterogeneity in the incidence of schizophrenia, which is thought to be related to a range 
of socioeconomic factors; e.g., urban vs. rural settings, the level of local social resources 
and the proportion of migrants in a host society, which represents a newly emerged risk 
group for schizophrenia (Pedersen and Mortensen, 2001, Cantor-Graae and Selten, 
2005, Coid et al., 2008, Kirkbride et al., 2008). In Finland the lifetime prevalence for 
schizophrenia is estimated to be 0.87% (Perälä et al., 2007).
2.1.2 THE MAIN CLINICAL DOMAINS OF SCHIZOPHRENIA, ITS COURSE AND 
OUTCOME
Schizophrenia is characterized by three main symptom domains: positive symptoms, 
negative symptoms and cognitive dysfunction (Tamminga and Holcomb, 2005). Positive 
symptoms typically include delusions, hallucinations (most commonly, auditory), a lack 
of insight and thought disorder. These symptoms tend to be more easily controlled than 
negative symptoms provided that antipsychotic medication is adequate. 
Negative symptoms of schizophrenia include social withdrawal, avolition, loss of 
motivation, emotional blunting and paucity of speech. In population-based samples, 
patients with primary negative symptoms comprise 15–20% of the patient population 
(Kirkpatrick et al., 2006). Negative symptoms contribute to a diminished level of daily 
functioning and quality of life, with increased social isolation. It is widely accepted that 
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negative symptoms generally respond less definitely to pharmacological treatment than 
positive symptoms (Erhart et al., 2006).
Schizophrenia-related cognitive impairment particularly includes the domains of 
attention, working memory and executive function (Goff et al., 2011). A growing body of 
evidence suggests that in schizophrenia, cognitive dysfunction may be an even more 
important determinant of outcome than either positive or negative symptoms (Keefe et 
al., 2005, Szöke et al., 2008). It is so far unclear whether or not the remediation of 
cognitive impairment in patients with schizophrenia can be achievable (Harvey et al., 
2008).
In addition to these core symptom domains, schizophrenia generally presents with a 
number of other symptoms, including depression, anxiety, mania, aggression, self harm 
and suicidal behavior.
During the course of schizophrenia, comorbid depression can be diagnosed in 
approximately 50% of patients (Buckley et al., 2009). The prevalence of depressive 
symptoms vary in different epidemiological studies, being from 5% (Lindenmayer et al., 
1991) to 83% (Hafner et al., 2005). Depressive symptoms are estimated to be more 
common in the acute phase and lower in the chronic phase of schizophrenia (Emsley et 
al., 1999, Lancon et al., 2001, An der Heiden et al., 2005). Comorbid depression 
significantly increases the risk for suicide (Heilä et al., 1997, Radomsky et al., 1999). It 
also negatively affects quality of life and level of functioning (Zizook et al., 1999), and is 
associated with more frequent relapses (Conley et al., 2007).
Schizophrenia may be characterized as a life-long disease with recurrent acute 
symptom exacerbations, and extensively varying degrees of functional disability 
(Robinson et al., 1999). Schizophrenia often has an acute onset, is episodic in its course, 
with some level of satisfactory recovery between episodes. Other patterns of this illness 
are characterized by an insidious onset, partial recovery, or a lack of recovery between 
episodes. In the most severe cases of this disease, a profound deterioration in 
psychosocial function occurs during the first few years of its course (van Haren et al., 
2012). In a large epidemiological study by An der Heiden and co-authors (1996), 60.7% 
of patients were symptomatic 14 years after the fist hospital admission, 12.5% were 
symptom-free while treated with antispychotics, and 26.8% were in remission.
2.1.3 PATHOPHYSIOLOGICAL BACKGROUND OF SCHIZOPHRENIA 
A number of disparate pathophysiological models have been proposed for an 
explanation of schizophrenia symptomatology. The most widely held neurochemical 
hypothesis is the classic hyperdopaminergic model (Carlsson and Lindquist, 1963, van 
Rossum, 1966), which postulates that psychotic symptoms in schizophrenia result from 
an excess of dopamine transmission. This theory emerged on basis of the observation 
that inhibition of dopamine metabolism in the brain improved psychotic symptoms (van 
Rossum, 1966) and this finding gained additional support from SPECT- and PET-based 
studies conducted in 1990 (Knable and Weinberger, 1997). According to this hypothesis, 
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patients with schizophrenia have an increased dopamine release into the synapse in 
mesolimbic areas during the acute phase of the disease, compared to healthy controls 
(Martinot et al., 1990, Kegeles et al., 2010). Functional neuroimaging studies also 
suggested that negative symptoms and cognitive dysfunction in schizophrenia may be 
connected to a deficit in dopamine neurotransmission at D1 dopamine receptors in 
medial prefrontal cortex (mPFC) (Goldman-Rakic et al., 2004, Castner and Goldman-
Rakic, 2004). Taken together, these theories formed a more complex and integrative 
model which postulates that schizophrenia is characterized by an imbalance between 
subcortical and cortical dopamine systems; e.g., subcortical mesolimbic dopamine 
projections may be hyperactive, thus resulting in hyperstimulation of D2 receptors and 
positive symptoms, while mesocortical projections to the mPFC may be hypoactive, thus 
resulting in hypostimulation of D1 receptors, the negative symptoms and cognitive 
impairment (Knable and Weinberger, 1997).
A more recently pathophysiological model for the etiology of schizophrenia focuses 
on an alteration in the glutamate neurotransmitter system, especially involving N-
Methyl-D-aspartic acid (NMDA) receptor function (Javitt and Zukin, 1991, Olney and 
Farber, 1995). This idea has emerged on the base of observations from reduced 
glutamate levels in the spinal fluid of patients with schizophrenia (Kim et al., 1980). A 
later observation noted that phencyclidine (PCP) abuse causes symptoms closely 
resembling schizophrenia (Lodge and Anis, 1982), which provided further support for 
the “glutamatergic” theory of schizophrenia. Recent SPECT studies in medication-free 
schizophrenic patients found NMDA receptor hypofunction in the hippocampus 
(Pilowsky et al., 2006). Antipsychotic treatment, especially with clozapine, attenuated 
this deficit (Bressan et al., 2005). Specific medications that therapeutically modify the 
glutamate system showed promising results in preclinical trials, but confirmation from 
RCTs has note yet been obtained (Buchanan et al., 2007, Tandon et al., 2010).
Some evidence indicates that gamma-Aminobutyric acid (GABA) neurotransmission 
is impaired in schizophrenia (Benes and Berretta, 2001, Lewis and Hashimoto, 2007). It 
has also been suggested that the cognitive deficits in schizophrenia may be related to 
alterations in GABA neurotransmission (Costa et al., 2001; Brigman et al., 2006). The 
potential role of GABAergic agents in the treatment of schizophrenia has not yet been 
established (Menzies et al., 2007). However there are add-on studies on mood 
stabilizers (see chapter 4.2.4).
Interest in a role for the serotonin system in the pathophysiology of schizophrenia 
began in the early 1960s (Axelrod and Inscoe, 1963), and developed further after the 
introduction of second-generation antipsychotics (SGAs), which are characterized by 
potent 5-HT2A receptor antagonism and relatively weak dopamine D2 receptor 
antagonism (Meltzer et al., 2008). However, in postmortem studies no consistent 
changes in the serotonin system of schizophrenia patients have been found (Harrison, 
1999), which makes it unclear as to what extent the serotonin system is involved in the 
pathophysiology of schizophrenia. It has been proposed that the antipsychotic effect of 
the SGAs may result from a serotonin-mediated modulation of dopamine release into 
the synapses (Marcus et al., 2000). This supposition is supported by the observation 
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that 5 HT2a receptor antagonists, without any affinity to dopamine receptors, exhibit 
antipsychotic activity both in animal and human studies (Kuroki et al., 2003).
Although the proposed pathophysiological theories of schizophrenia seem rather 
disparate and inconclusive, there may be a common ground for several 
neurotransmitter abnormalities occurring at the same time. A growing body of evidence 
suggests that alterations in glutamate receptor functioning may, in turn, contribute to 
the development of the GABAergic pathology associated with schizophrenia (Keshavan, 
2011). Both glutamatergic and GABAergic disfunction may lead to severe imbalances 
between the excitatory and inhibitory systems of the brain, possibly forming a 
fundamental deficit for schizophrenia, while monoaminergic dysfunction could be a 
secondary result of this imbalance (Miyamoto et al., 2012).
2.2 PHARMACOLOGICAL TREATMENT OF SCHIZOPHRENIA
2.2.1 ANTIPSYCHOTIC TREATMENT: CURRENT RECOMMENDATIONS
A number of treatment guidelines exist for schizophrenia (APA, 2004, Suomen 
psykiatriyhdistys, 2008, APA, 2009, NICE, 2009, Barnes et al., 2011). Though varying 
in detail, these treatments generally accept that dopamine antagonists (antipsychotics) 
represent the only class of drugs that have awidely proven efficacy in the treatment of 
schizophrenia (Barnes et al., 2011). It has been recommended that treatment with 
antipsychotics should begin at the early stages of schizophrenia, thus forming a critical 
part of early intervention strategy. This approach is based on the presumption that 
treatment should begin at an early and relatively treatment-responsive stage of the 
disease, to minimize possible negative consequences of an active morbid process, and to 
subsequently improve both symptomatic and functional outcomes (Marshall et al., 
2005, Perkins et al..2005). It has also been hypothesized that antipsychotic treatment at 
the first episode of schizophrenic psychosis can prevent the progression of structural 
brain changes (Li and Xu, 2007, Lieberman et al., 2005, 2008). Consensus guidelines 
recommend the continuation of antipsychotic treatment in patients with established 
schizophrenia for at least one or two years (Buchanan et al. 2010; NICE, 2009).
Several naturalistic studies have demonstrated that only 20% of patients did not 
experience another episode during a 5-year follow-up after the first psychotic episode, 
(Shepherd et al., 1989, Robinson et al., 1999). In patients with a history of multiple 
episodes, the expected frequency of relapse is presumably higher, which justifies 
continuous maintenance treatment with antipsychotics (Leucht et al., 2012). It has been 
established that maintenance treatment with antipsychotics reduces relapse rates. For 
instance, Gilbert and co-authors (1995) found the reduction of relapse risk from 53% to 
16% within 10 months of maintenance treatment. Intermittent treatment has been 
found to be less efficacious when compared to continuous treatment in several studies 
(Carpenter et al., 1990, Schooler et al., 1997, Gaebel et al., 2010).
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First-generation antipsychotics (FGAs).
FGAs emerged in the early 1950s, when the efficacy of chlorpromazine in the 
treatment of psychotic symptoms was first described (Delay, 1952). In the following 
decades, a large number of other phenothiazine compounds and antipsychotics of other 
chemical classes (e.g., butyrophenones, tioxantenes, etc.) were introduced. Although 
nearly six decades have passed since the introduction of the first FGA, this group of 
psychotropic drugs is still in wide use, and is still considered to be effective in treating of 
schizophrenia, especially the psychotic symptoms (Lieberman et al., 2005, Leucht et al., 
2009). The clinical efficacy of FGAs is believed to result from their ability to inhibit the 
brain dopamine D2 receptors (Carlsson and Lindqvist, 1963), although these drugs 
affect some other neurotransmitter systems, e.g. serotonin and acetylcholine
While generally effective in the treatment of psychosis, FGAs are associated with 
numerous adverse effects; for example, extrapyramidal symptoms (EPS), 
hyperprolactinemia, anticholinergic effects and others (see Section 4.2.2.). Another 
problem is that the efficacy of FGAs on negative symptoms of schizophrenia has been 
repeatedly questioned (Meltzer, 1999).
Second-generation antipsychotics (SGAs).
Attempts to develop effective antipsychotics with a better tolerability profile led to 
the introduction of the second-generation antipsychotics, which are also known as the 
“atypical” antipsychotics. The era of SGAs began in 1959 with the introduction of 
clozapine, the first SGA and, in a pharmacological sense, the prototypical SGA (Meltzer, 
2012). In recent decades, SGAs became the most widely prescribed pharmacological 
treatment for schizophrenia (Aparasu et al., 2005). Despite reliable experience in the 
use of SGAs, an uncertainty regarding the definition of their “atypicality” still exists 
(Meltzer et al., 2001). The most commonly used principle for distinguishing between 
typical and atypical antipsychotics is based on the differences between their 
mechanisms of action. In particular, SGAs are believed to exhibit a more potent 
blockade of 5-HT2a (Meltzer et al., 1994), while FGAs function primarily by blocking the 
dopamine D2 receptor. SGAs are considerably less associated with EPS, yet also have 
their own collection of adverse effects, e.g. negative influence on lipid and glucose 
metabolism, weight gain, haematological side-effects (with clozapine), along with some 
other unwanted effects (Volavka et al., 2002, see section 4.2.2).
The comparative efficacies of FGAs and SGAs have been a subject of extensive 
research, as can be seen in modern meta-analyses of this topic, which include hundreds 
of RCTs. Despite an enormous number of comparative RCTs, the question regarding the 
relative efficacy of FGAs and SGAs still appears to be unanswered. Some meta-analyses 
of RCTs that compare FGAs and SGAs found the latter group to be superior in terms of 
overall efficacy. For example, a meta-analysis by Davis and co-authors (2003) found 
that clozapine, amisulpride, risperidone, and olanzapine were more effective than FGAs. 
In another meta-analysis, Leucht and co-authors (2009) found that these same four 
SGAs were superior to FGAs with regard to general efficacy. Worth mentioning is that 
the magnitude of this favourable efficacy was defined by the authors as small, with the 
frequency of adverse effects for the FGAs being much more prominent (Leucht et al., 
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2011). Geddes and co-authors did not find any difference in their meta-analysis (2000) 
when the efficacy between FGAs and SGAs was compared. Moreover, in several large 
effectiveness studies, namely Clinical Antipsychotic Trials of Intervention Effectiveness 
Study (CATIE) (Lieberman et al., 2005), Cost Utility of the Latest Antipsychotic Drugs 
in Schizophrenia Study (CUtLASS) (Jones et al., 2006) and The European First Episode 
Schizophrenia Trial (EUFEST) (Kahn et al., 2008), no clear superiority was found in the 
effectiveness of SGAs over FGAs. In CATIE, olanzapine-treated patients showed a 
slightly longer time for discontinuation than other antipsychotics, while perphenazine 
(an FGA comparator) showed a comparable degree of effectiveness when compared with 
other SGAs (Lieberman et al., 2005). Similarly in CUtLASS, no major differences in 
effectiveness were found between FGAs and SGAs (Jones et al., 2006). In EUFEST, 
olanzapine was superior to haloperidol with regard to the time to discontinuation, while 
another outcome measure, symptom reduction, was nearly indistinguishable in all 
treatment groups (Kahn et al., 2008). Taken together, these results suggest that there 
may not be any significant overall differences between FGAs and SGAs in regard to 
improvement in psychopathology. The only exception from this is  clozapine, which has 
been consistently shown to be superior to other antipsychotics in treatment-resistant 
schizophrenia (McEvoy et al., 2006, Leucht et al., 2009). Given the lack of a significant 
efficacy between antipsychotics, the key issues influencing the choice of an antipsychotic 
for an individual patient with schizophrenia should be the side-effect profile, the 
potential to improve cognition and the prevention of relapse (Meltzer, 2012). 
2.2.2 MAIN RISKS DUE TO ANTIPSYCHOTIC TREATMENT
The use of FGAs is associated with a broad range of adverse effects, which are often 
severe and sometimes irreversible, as is in the case of tardive dyskinesia, which impairs 
general health, level of functioning and quality of life for the FGA-treated person, and 
also negatively affects the adherence to treatment (Kane and Correll, 2010). FGAs are 
known to cause different extrapyramidal symptoms; i.e., parkinsonism, dystonia, 
akatisia and tardive dyskinesia (Miyamoto et al., 2012). The estimated overall 
prevalence of EPS in patients with schizophrenia varies widely between 29 and 74% 
according to different reports (McCreadie et al., 1992, van Harten et al., 1996, Modestin 
et al., 2000). In the Nithsdale schizophrenia survey, which assessed the prevalence of 
antipsychotic-induced parkinsonism, akatisia and tardive dyskinesia among patients 
with schizophrenia, the corresponding prevalences were 27%, 18% and 25%, 
respectively, (McCreadie et al., 1992). These EPS are thought to result from a blockade 
of dopamine D2 receptors located in the nigrostriatal area. This is why the more potent 
D2 blockers are associated with a more significant risk of both acute and late-onset EPS 
(Agnoli et al., 1983). Other side-effects of FGAs include anticholinergic effects (such as 
dry mouth), postural hypotension, weight gain, hyperprolactinemia (with subsequent 
sexual dysfunction) and a lowering of the seizure threshold (Meyer, 2007). A potentially 
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lethal, yet fortunately rare complication of FGA treatment is the malignant neuroleptic 
syndrome (Trollor, 2012).
For these reasons, the introduction of SGAs was accompanied with much optimism 
in regard to their advertised safety and tolerability profiles. Indeed, the lower degree of 
D2 antagonism, when compared to FGAs, makes SGAs seem less prone to cause 
neurological side-effects (Meltzer, 2012). However, later RCTs showed that SGAs are not 
fully devoid of EPS (Miller et al., 2008), the risk of neuroleptic malignant sydrome 
(Trollor et al., 2012) and hyperprolactinemia (Cookson et al., 2012). Moreover, SGAs are 
associated with their own set of detrimental side-effects; i.e., metabolic complications
that include weight gain, hyperglycaemia and dyslipidemia (Newcomer, 2007, De Hert 
et al., 2009). Clozapine, the most effective SGA, also bears an inherent range of harmful 
side-effects, such as haematological complications, myocarditis, seizures, weight gain, 
constipation and excessive sedation (Kane, 1998). In particular, the risk of 
agranulocytosis has led to limitations of clozapine’s use, which is currently restricted in 
many countries to refractory patients (NICE, 2009).
Interestingly, there appears to be a relationship between the efficacy and metabolic 
effects of antipsychotics, at least in the case of SGAs. Clozapine and olanzapine both 
have an untoward profile of metabolic side-effects. Clozapine has repeatedly showed 
superiority in efficacy over other antipsychotics and, in some reviews olanzapine also 
demonstrated similar properties (Leucht et al., 2009). It has been repeatedly shown in 
RCTs that these antipsychotic-related metabolic adverse effects are directly associated 
with an improvement in psychopathology. Meltzer and co-authors (2003), for example, 
reported an association between weight gain and clinical improvement in clozapine-
treated patients. In an RCT by Procyshyn and co-authors (2007), clozapine-induced 
changes in lipid profile were correlated with its clinical efficacy, yet independently of 
weight change. In a study by Ascher-Svanum and co-authors (2005) olanzapine-induced 
weight gain significantly correlated with better treatment response. More recently 
Hermes et al. (2011) reported similar results for various FGAs and SGAs in the CATIE 
study, where a 0.28 point decrease in PANSS total score was associated with a 1% 
increase in body mass index (BMI). The nature of this relationship is unclear (Procyshyn 
et al., 2007). It has been hypothesised that low serum cholesterol may contribute to 
poor treatment response in patients with schizophrenia by decreasing central serotonin 
function (Hawton et al., 1993). Thus, clozapine might “repair” this dysfunction by 
increasing lipid levels. However, it remains unclear whether or not such changes in 
weight and metabolic parameters directly influence clinical improvement, are a 
consequence of this, or are a covariate or some other mediating factor (Ascher-Swanum 
et al., 2005). Clearly, this particular issue also requires further investigation (Meltzer, 
2012).
There appears to be only very modest differences in clinical efficacy between 
different antipsychotic drugs (with the sole exception of clozapine and, with some 
degree of controversy, olanzapine), and no convincing data exists to support an effective 
targeting strategy for treating particular symptoms of schizophrenia with particular 
antipsychotics. Thus, the available data on the specific adverse effect profiles of 
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antipsychotics have a considerable influence on drug choice for the treatment of 
schizophrenia (Barnes et al., 2011). 
2.2.3 TREATMENT-RESISTANT SCHIZOPHRENIA: CURRENT CLINICAL
APPROACHES
The term “treatment-resistant” is generally attributed to cases where schizophrenia has 
not responded sufficiently to treatment. There still exist some controversies in defining 
this phenomenon. According to one of the definitions, treatment-resistant patients “had 
previously failed to respond to, or were intolerant of at least two different classes of 
antipsychotic drugs given in appropriate doses for at least 4 weeks each” (Bondolfi et al., 
1998). Another definition uses a wider clinical concept of “incomplete recovery”, which 
means that the presence of “lasting disability in functional and psychosocial aspects 
despite psychological/psychosocial and pharmacological interventions” (Pantelis and 
Lambert, 2003).
Treatment resistance is a relatively common phenomenon in schizophrenia. It has 
been estimated that between a fifth and a third of patients with schizophrenia 
demonstrate a poor response to adequate regimes of antipsychotic treatment 
(Lieberman et al., 1996; Conley and Buchanan, 1997, Pantelis and Lambert, 2003). This 
proportion seems to increase with the progression of the disease, as the failure to 
achieve remission among first-episode patients is estimated to be at about 10% (Crow et 
al., 1986; Lambert et al., 2008), and with every new relapse one of six patients will not 
remit from the episode of illness, despite pharmacological treatment (Wiersma et al., 
1998). There is a growing body of evidence to suggest that treatment resistant 
schizophrenia has its own neurobiological correlates, with an underlying 
pathophysiology that most likely involves other neurochemical abnormalities than a 
dopamine imbalance (Altamura et al., 2005, Stone et al., 2010). 
The efficacy of clozapine for treatment-resistant schizophrenia has been clearly 
demonstrated by Kane and co-authors (1988, 2001), and a few subsequent meta-
analyses have supported the superiority of clozapine over both FGAs and SGAs 
(Wahlbeck et al., 1999, Chakos et al., 2001, Asenjo-Lobos et al., 2010). Thus, clozapine 
remains the “gold standard” for treatment-resistant schizophrenia (Leucht et al., 2011, 
Volavka, 2012) and is recommended for this purpose by the most clinical guidelines. 
Another treatment strategy for treatment-resistant schizophrenia employs 
combinations of antipsychotic drugs (including combinations with clozapine), but 
evidence supporting the feasibility of this approach is both limited and contradictory 
(Goodwin et al. 2009). This also seems to be true for the augmentation of antipsychotic 
therapy with medications from other classes of drugs, with the only probable exception 
of clozapine augmentation with lamotrigine (Tiihonen et al., 2009). This apparent 
exception is discussed in Section 4.2.4.
To summarize, clozapine remains the most effective treatment option for treatment-
resistant schizophrenia, while other treatment strategies have not yet gained enough 
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support from clinical studies. However, the available evidence suggests that only 30 to 
60% of patients with treatment-resistant schizophrenia will achieve a satisfactory 
response to clozapine (Iqbal et al., 2003). Moreover, treatment with clozapine is 
associated with a number of adverse effects, some of them serious and potentially fatal. 
Thus, a need remains for effective treatment strategies.
2.2.4 ADD-ON TREATMENTS FOR SCHIZOPHRENIA
As stated earlier, treatment with antipsychotics alone is not always enough to achieve a 
good clinical outcome in schizophrenia. This observation corresponds to a need for new 
pharmacological strategies that improve treatment results. One such strategy is 
adjuvant treatment, where ongoing antipsychotic therapy is augmented with a drug 
from another class of medicines. The most widely used augmentation strategies that 
target schizophrenic symptoms include mood stabilizers; e.g. valproate (Schwarz et al., 
2008), lamotrigine (Tiihonen et al., 2009), lithium (Leucht et al., 2007) and 
antidepressants; e.g., tricyclic antidepressants (TCAs, Siris, 1993), selective serotonin 
reuptake inhibitors (SSRIs, Sepehry et al., 2007) and other receptor-blocking 
antidepressants (Singh et al., 2010). Other augmentation strategies include sex 
hormones (Ko et al., 2008), cyclo-oxygenase (COX) inhibitors (Riedel et al., 2005), 
glutamatergic drugs (Tuominen et al., 2006), acetylcholine esterase inhibitors (Keefe et 
al., 2008) and sildenafil (Akhondzadeh et al., 2011).
Only a few adjuvant medicines have so far been included in the international 
treatment guidelines. These include the augmentation of ongoing clozapine treatment 
with lamotrigine (Barnes et al., 2011) and the augmentation of FGA or SGA treatment 
with antidepressants for either symptoms of depression (APA, 2004) or persistent 
negative symptoms (Barnes, 2011). Mood stabilizers are recommended by the APA for 
prominent mood lability and aggression (APA, 2004). Overall, the evidence regarding 
efficacy and tolerability of adjunctive treatments is still inconclusive and requires 
further investigation (Leucht, 2011).
2.3 THE ROLE OF ADJUNCTIVE ANTIDEPRESSANTS IN THE 
TREATMENT OF SCHIZOPHRENIA
The existing treatment guidelines do not yet suggest antidepressants for the treatment 
of negative or positive symptoms of schizophrenia. For instance, the Practice Guideline 
for the Treatment of Patients with Schizophrenia by the APA recommends the 
consideration of antidepressants for treatmenting comorbid major depression, yet 
suggests caution due to a possible risk for an exacerbation of the psychosis (APA, 2004). 
Similarly, the NICE guideline by the British Royal College of Psychiatrists suggests 
limiting the antidepressant augmentation of antipsychotics only for the treatment of 
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“comorbid or secondary psychiatric problems, such as depression and anxiety” (NICE, 
2009).
Nevertheless, in actual practice clinicians widely use antidepressants to treat co-
occurring depression, posttraumatic stress disorder or anxiety in psychotic patients 
(Zink et al., 2010, Himelhoch et al., 2012). For example in the CATIE study, 
approximately a third of the participants with schizophrenia were receiving an 
antidepressant at the study baseline (Chakos et al., 2006).
2.3.1 EFFICACY OF ANTIDEPRESSANTS IN THE TREATMENT OF POSITIVE, 
NEGATIVE AND AFFECTIVE SYMPTOMS
Antidepressants as an adjuvant treatment for schizophrenia have been a subject of 
extensive clinical research for many years. The results of RCTs with add-on 
antidepressants are summarized in Table 1. 
In earlier studies, the rationale for the use of adjuvant antidepressants was based on 
the observation of an existing clinical overlap between some symptoms of schizophrenia 
and depression; e.g., apathy, anhedonia and avolition, and a presumption of stimulating 
effects from antidepressants (Waehrens and Gerlach, 1980). Studies with TCAs in the 
1980s yielded mainly positive results, but their conclusions seem to be questionable, 
mainly due to some substantial methodological limitations, especially in regard to the 
applied outcome measures (Rummel-Kluge et al, 2006). 
In the 1990s, the focus of research on biological mechanisms in schizophrenia 
targeted the serotonin system. In particular, the adjunctive SSRIs were hypothesized to 
affect negative symptoms by enhancing synaptic availability of serotonin for 
neurotransmission, with a subsequent re-setting of the dysfunctional serotonergic 
system (Laruelle et al., 1993, Dean et al., 1996). The efficacy of individual SSRIs as an 
add-on treatment for schizophrenia vary widely, and most evidence exists for their 
efficacy on negative symptoms (Zullino et al., 2002, Rummel-Kluge et al., 2006), while 
no support exists from RCTs to justify their use in their treatment of positive or 
depressive symptoms. A theoretical basis for the probable efficacy of selective 
noradrenaline reuptake inhibitors (SNRIs) in the adjunctive treatment of schizophrenia 
relies on the assumption that noradrenergic hypoactivity may be associated with 
negative symptoms (Yamamoto and Hornykiewicz, 2004). Therefore, enhancing the 
transmission in noradrenergic pathways of the brain may lead to a corresponding 
reduction in negative symptoms. 
The available evidence regarding the efficacy of add-on treatment with SNRIs in 
schizophrenia is also mixed and scarce (Table 1). 
Another group of antidepressants – the so-called receptor blocking antidepressants 
act via the inhibition of various monoamine receptor subtypes. The rationale for the 
combining of these antidepressants with antipsychotics in the treatment is based on the 
theory of atypicality; e.g., antipsychotics with 5HT2-receptor blockade prevailing over 
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D2-receptor blockade (from atypical, or SGAs) are more effective in regard to positive, 
negative, and cognitive symptoms than the pure D2-blockers (typical, or FGAs, Meltzer, 
1999, Meltzer et al., 2011). According to this assumption the combination of a 5HT2-
inhibitor with a D2-inhibitor would mimic or, at least resemble the receptor binding 
profile of SGAs with corresponding favorable clinical effects with less side effects 
(Berendsen et al., 1998, Berk et al., 2001). 
Of these drugs, trazodone, mianserin and mirtazapine have been studied in several 
RCTs (Table 1). The vast majority of these studies point to the efficacy of add-on 
treatment with receptor-blocking antidepressants on the negative symptom domain of 
schizophrenia. Mirtazapine appears to have demonstrated the most consistant findings.
To summarize, Rummel-Kluge and co-authors concluded in their Cochrane review 
(2006) that “the combination of antipsychotics and antidepressants may be effective in
treating negative symptoms of schizophrenia...”, though the information from RCTs can 
still be characterized as limited. In their meta-analysis on the same topic, Singh and co-
authors (2010) based their comparison of effect sizes for different antidepressants, and 
suggested that the most effective drugs for treating the negative symptoms are 
ritanserin, trazodone and fluoxetine (NNT 5, 6 and 11, correspondingly). It should be 
noted, however, that ritanserin (an antagonist of 5-HT2A and 5-HT2C receptors) is not 
currently marketed as an antidepressant.
Current evidence is still insufficient to recommend any of the existing 
antidepressants for the treatment of positive symptoms in schizophrenia. Nevertheless, 
the use of add-on antidepressants appears to be a safe treatment strategy, because in the 
above listed RCTs no additional risk worsening psychosis has emerged. This seems to be 
true at least for chronic schizophrenia, while it has been recommended to avoid the use 
of antidepressants during the acute stage of psychosis (Leucht et al., 2011). 
Add-on antidepressants may be beneficial in the treatment of depression in the 
patients with schizophrenia (Leucht et al., 2011, Whitehead et al., 2012), although this 
research data is far from convincing and further research is needed. 
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2.3.2 EFFICACY OF ANTIDEPRESSANTS IN THE TREATMENT OF EPS
The supposition that add-on antidepressants may alleviate antipsychotic-induced EPS 
derives from the idea of dopamine deficit in the basal ganglia of brain. According to this 
theory, pharmacological agents that increase available dopamine in this area may be 
used to treat EPS (Meltzer et al., 2003, Ohno, 2011). Another possible effective 
mechanism could be through 5HT2 receptor antagonism – a common feature of several 
receptor-blocking antidepressants (Berk et al., 2001). 
The research data regarding the efficacy of receptor-blocking antidepressants on 
antipsychotic-induced EPS are contradictory (Table 1). Findings from several RCTs with 
add-on mirtazapine, mianserin and trazodone to existing antipsychotic therapy suggest 
a probable efficacy of these antidepressants, while findings from some other studies 
with the same agents do not.
There is no proven mechanism for the possible efficacy of TCAs, SSRIs or SNRIs in 
the treatment of antipsychotic-induced EPS. Moreover, these antidepressants may 
themselves even cause EPS in patients with major depressive disorder (MDD, 
Madhusoodanan et al., 2010). Nevertheless, the influence on EPS was a secondary 
variable in a number of studies with SSRIs and SNRIs, as listed in the section 4.3.1. 
Perhaps, not surprisingly, all these studies gained negative results.
2.3.3 EFFECTIVENESS OF ANTIDEPRESSANTS IN SCHIZOPHRENIA
Only a few effectiveness studies have focused on adjuvant antidepressants in 
schizophrenia. In a large study by Tiihonen and co-authors (2012), relationships 
between polypharmacy and mortality rates were investigated in a nationwide cohort of 
2588 patients suffering from schizophrenia and hospitalized for the first time between 
January 2000 and December 2007. According to their results, concomitant 
antidepressant treatment was associated with lessened mortality from all causes (HR 
0.57; 95% CI 0.28-1.16) and particularly from suicide (HR 0.15; 95% CI 0.03-0.77).
In another recent prospective study conducted by Laengle and co-authors (2012), the 
effects of psychotropic polypharmacy (including antidepressants, benzodiazepines, and 
mood stabilizers) on clinical outcomes and quality of life were analyzed in a cohort of 
374 patients with schizophrenia and schizoaffective disorder who received different 
SGAs. Patients were assessed with the PANSS, the Global Assessment of Functioning 
(GAF), the Lancashire Quality of Life Profile, SAS, and Abnormal Involuntary 
Movement Scale (AIMS) in a 24 month follow-up. In that study, patients receiving 
combinations of SGAs with antidepressants did not differ in terms of clinical outcomes, 
as measured by PANSS, from patients receiving antipsychotic monotherapy. Moreover, 
therapy with a SGA-antidepressant combination was associated with a more significant 
improvement in EPS than all other treatments, including monotherapy with SGAs. 
Worth noting from the same study is the mean baseline PANSS scores ranging from 
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49.8 to 57.7, thus making it unclear whether or not these findings can be extrapolated to 
patients with more severe illness.
Glick and co-authors (2006) evaluated the clinical effect for the gradual 
discontinuation of antidepressant treatment in a sample of 22 patients stabilized on an 
antipsychotic medication. The outcome was measured with the Clinical Global 
Impression-Improvement Scale (CGI-I) during a 3 to 12 months of follow-up. Tapering 
off an antidepressant led to a decline of a patient’s mental condition in one case, 
whereas in 18 cases the situation remained stable, while in 3 cases the patients’ mental 
state improved. This led the authors to conclude that tapering off the concomitant 
antidepressant treatment does not change the outcome. Based on this observation, 
clinicians are now encouraged to try and withdraw stabilized chronic patients from their 
adjunctive antidepressant medications, provided that their antipsychotic dosage is 
adequate. These authors did not use other outcome measures, nor did they report on
other patient characteristics (e.g., presence of depressive symptoms or EPS, severity and 
duration of the disease, etc), which makes it difficult to extrapolate this finding on to 
certain patient groups, for example, patients with schizophrenia and depression, 
patients with predominantly negative symptoms, etc.
In a recent large (n= 16.083) nationwide study in Finland, Suokas and co-authors 
(2012) found that antidepressant use was associated with a decreased risk of 
antipsychotic polypharmacy in patients with schizophrenia. This finding was statistically 
significant in patients with chronic schizophrenia, and there was also a trend towards 
improvement in patients with recent-onset schizophrenia.
Thus, it can be concluded that in real-life clinical settings there should be no reasons 
for concern about the safety of antidepressants in schizophrenia patients. Moreover, 
antidepressants seem to decrease mortality in schizophrenia patient cohorts, 
presumably by the prevention of suicide and other forms of self harm.
2.4 MIRTAZAPINE
2.4.1 PHARMACOLOGICAL PROFILE AND CLINICAL EFFICACY
Mirtazapine is a pharmacological agent from the group of second generation 
antidepressants (SGAs). Mirtazapine has a unique receptor profile, being an antagonist 
of central pre-synaptic alpha-2-adrenoreceptors, postsynaptic 5-HT2a, 5-HT2c, 5-HT3, 
and histamine H1 receptors. In addition, mirtazapine exhibits indirect agonism at 5-
HT1a receptors (de Boer, 1996). 
Through blockade of central alpha-2-adrenergic autoreceptors, mirtazapine causes 
an increase in the release of noradrenaline. The subsequent stimulation of 
somatodendric alpha-1-receptors, which mediate the firing of serotonin neurons, along 
with a direct blockade of inhibitory alpha-2-heteroreceptors on 5-HT terminals is 
thought to lead to an increase in hippocampal serotonin release (Gillman, 2006). 
Enhanced serotonin neurotransmission is, in this case, specifically mediated via the 5-
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HT1 receptor, which is thought to be responsible for the therapeutic effects of some 
antidepressants. Unlike other antidepressants (SSRIs, SNRIs, TCAs, Inhibitors of the 
Monoamine Oxidase [IMAOs]) that stimulate serotonergic receptors by increasing 
available serotonin, mirtazapine selectively blocks 5-HT2 and 5-HT3 receptors, which 
makes this antidepressant free of the adverse effects typical for other classes of 
antidepressive drugs (e.g., sexual dysfunction, gastrointestinal problems, etc.) (Gillman, 
2006). Moreover, inhibition of 5-HT2 and 5-HT3 receptors may contribute to the 
anxiolytic and somnoforic effects of mirtazapine (de Boer, 1996). Histamine H1 receptor 
blockade is believed to contribute to side-effects of mirtazapine, e.g., sedation, increased 
appetite and weight gain (Stimmel et al., 1997).
Mirtazapine is an antidepressant with established efficacy in the treatment of major 
depression (Benjamin and Doraiswamy, 2011). According to a Cochrane review by 
Watanabe and co-authors (2011), the effect of mirtazapine is comparable to TCAs (OR 
0.89, 95% CI 0.72 to 1.10) and superior over both SSRIs (OR 1.19, 95% CI 1.01 to 1.39) 
and SNRIs (OR 1.53, 95% CI 1.03 to 2.25), in terms of response during the acute-phase 
treatment (6 to 12 weeks) of MDD. Mirtazapine has been listed as being among the most 
effective antidepressants in some (Watanabe et al., 2008, Cipriani et al., 2009), though 
not all (Hansen et al., 2005) systematic reviews. Furthermore, there is consistent 
evidence from a number of RCTs demonstrating that mirtazapine has a faster onset of 
action in patients with MDD than the majority of other antidepressants (Gartlehner et 
al., 2011).
2.4.2 SAFETY AND TOLERABILITY OF MIRTAZAPINE
Mirtazapine is generally well tolerated, with an overall incidence of reported adverse 
effects comparable to that of a placebo (Montgomery, 1995), and most adverse events 
seen with mirtazapine treatment are mild and transient, and as a rule decreasing in both 
intensity and frequency over time (Fawsett and Barkin, 1998). Adverse events that are 
most frequently encountered with mirtazapine vs. placebo are dry mouth (25% vs. 16%), 
drowsiness (23% vs. 14%), excessive sedation (19% vs. 5%), increased appetite (11% vs. 
2%) and weight gain (10% vs. 1%) (Montgomery, 1995). Noticeably, sedation and 
drowsiness are related to low doses and either diminish or gradually disappear during 
titration to higher doses (Bremner, 1995). It has been hypothesized that the 
noradrenergic activation induced by mirtazapine at higher dosages overrides its 
antihistaminic activity (Barkin et al., 1999). The incidence of serotonin-related adverse 
gastrointestinal effects (e.g., nausea, vomiting, diarrhea) are either comparable or 
somewhat lower in mirtazapine than in placebo, and the incidence of agitation, 
restlessness or insomnia are comparable with both mirtazapine and placebo (Fawsett 
and Barkin, 1998). Treatment with mirtazapine is associated with a much lower risk of 
sexual dysfunction when compared with SSRIs (Benkert et al., 2000) and SNRIs 
(Gartlehner et al., 2011). Interestingly, in a study by Gelenberg and co-authors (2000), 
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patients suffering from SSRI-related sexual dysfunction did benefit from a switch to 
mirtazapine treatment, with no loss in antidepressive response.
Mirtazapine has a wide therapeutic index and is relatively safe in overdose situations 
(Montgomery, 1995). Being a very weak inhibitor of cytochrome P450 hepatic 
isoenzymes, it has a low propensity for drug–drug interactions (Timmer et al., 2000, 
Dodd et al., 2001).
During the clinical development program, no significant changes in laboratory 
parameters or cardiovascular vital signs (e.g., heart rate, blood pressure) occurred with 
mirtazapine treatment (Montgomery, 1995). Data from more recent studies mainly 
confirmed the established safety of mirtazapine from the viewpoint of glucose 
metabolism (Laimer et al., 2006, Hennings et al., 2012). However, there is a growing 
body of evidence that point to an unfavorable effect of mirtazapine on serum lipid 
parameters; i.e., LDL-cholesterol and triglycerides (Laimer et al., 2006, McIntyre et al., 
2006). This effect is thought to be a secondary to the well-established propensity for 
mirtazapine to induce weight gain, rather than a direct influence of mitrazapine on lipid 
metabolism (McIntyre et al., 2006).
2.4.3 RATIONALE FOR THE USE OF MIRTAZAPINE AS AN ADD-ON 
TREATMENT FOR SCHIZOPHRENIA
The explanation for the efficacy of mirtazapine as an adjunctive treatment for 
schizophrenia is based on its receptor profile. As stated previously, mirtazapine is a 
potent inhibitor of postsynaptic 5-HT2a receptors that lacks noteworthy D2 receptor 
affinity, and thus antipsychotic efficacy. Subsequently, the combination of mirtazapine 
with a D2 antagonist (i.e., FGA) may provide a beneficial strategy with improved efficacy 
and tolerability. Other pharmacodynamic properties of mirtazapine, e.g. inhibition of 5-
HT3 and alpha adrenoreceptors, may also be useful. In addition, mirtazapine can 
presumably be safely combined with most conventional antipsychotics, as it does not 
significantly inhibit liver CYP 450 enzymes, which are responsible for the metabolism of 
many antipsychotics. To date however, there is not enough data on the feasibility of this 
strategy. The only previous RCT on a mirtazapine-FGA combination (Berk et al., 2001) 
examined just one antipsychotic (haloperidol 5 mg daily) in a group of 15 patients. Thus, 
more studies are needed, especially in settings that resemble clinical practice (i.e., 
treated with different FGAs), before adjunctive mirtazapine in schizophrenia can be 
recommended.
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3 AIMS OF THE STUDY
1. To explore the effect of short- and middle-term adjunctive mirtazapine on the
positive and negative symptoms of schizophrenia in patients with no or only sub-
optimal response to different FGAs in stable dosages.
2. To obtain data on the effects of short- and middle-term adjunctive mirtazapine on
affective symptomatology in FGA-medicated patients with schizophrenia.
3. To evaluate whether or not adjunctive mirtazapine is able to diminish FGA-
induced side effects.
4. To investigate safety and tolerability of mirtazapine in patients with
schizophrenia.
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4 SUBJECTS AND METHODS
4.1 STUDY DESIGN
The study was a single-center add-on placebo-controlled RCT. Patients were recruited 
from the Psychiatric Hospital and the Day Treatment Unit of the Psychoneurological 
Dispensary of the Karelian Republic, Petrozavodsk, Russia. 
4.2 INCLUSION AND EXCLUSION CRITERIA
4.2.1 INCLUSION CRITERIA
Male or female in- or out-patients who met the following criteria:
1) aged 18 - 65 years,
2) a diagnosis of DSM-IV (APA, 1994) defined schizophrenia (disorganized,
catatonic, paranoid, residual, or undifferentiated) or schizoaffective disorder, depressive 
type,
3) currently receiving one or more FGA at a cumulative daily dose of at least 200 mg
chlorpromazine equivalents, which has remained unchanged (also in terms of dosage) 
for at least six last weeks prior to screening (eight weeks for depot antipsychotics),
4) have demonstrated less than optimal clinical outcome, i.e. experience either
positive or negative symptoms (disability due to only general symptoms was insufficient 
for inclusion) resulting in an illness of at least moderate severity (i.e. a rating of 4, 
moderately ill, or more on the CGI severity item, Guy, 1970),
5) the clinical condition has remained stable during the last six weeks prior to the
baseline visit,
6) the patient had a level of understanding that enabled reasonable cooperation with
the investigator, 
7) the patient had given written informed consent.
4.2.2 EXCLUSION CRITERIA
1) a history of allergy or serious adverse events due to mirtazapine,
2) a previous lack of response to a trial with mirtazapine at a daily dosage of 30 mg or
more during four or more weeks, when added to the patient’s current or earlier 
conventional antipsychotic medication,
3) a previous lack of response to another antidepressant with affinity to postsynaptic
5-HT2 receptors (e.g.; mianserine, trazodone, or nefazodone,) used at adequate doses 
during four or more weeks,
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4) current atypical antipsychotic medication (e.g.; clozapine, risperidone, olanzapine,
sertindole, quetiapine, zotepine, ziprasidone, etc.)
5) a history of non-response to either clozapine or other atypical antipsychotics,
6) a medical or neurological condition or drug treatment which might cause a serious
risk for the patient, or bias the assessment of their clinical or mental status (e.g.; serious 
unstable physical illness, epilepsy, “organic” brain syndrome, etc.),
7) a history of or current bipolar disorder or schizoaffective disorder, bipolar type
(patients with schizoaffective disorder, depressive type could participate in the study).
8) substance addiction or abuse within the last three months prior to screening,
9) clearly predictable poor compliance,
10) suicidality,
11) for females of child-bearing potential: pregnancy, lactation, or an inability or
unwillingness to use medically acceptable methods of contraception during the study,
12) treatment with any antidepressant, mood stabilizer, regular (i.e. four or more
times within one week) use of sumatriptan, naratriptan, zolmitriptan, or drugs with a 
similar mechanism of action, or buspirone or drugs with a similar mechanism of action - 
within four weeks (for fluoxetine six weeks) prior to baseline. Accidental use of the 
above listed drugs for the treatment of migraine was not allowed on the day of clinical 
assessment or just before the assessment,
13) treatment with antipsychotics other than those currently used within 6 weeks
prior to baseline,
14) treatment with benzodiazepines as follows:
-regular use (i.e. four or more times weekly) of any benzodiazepines at any dosage 
during the last four weeks prior to baseline, if they have been started for less than two 
months ago. However, regular use of benzodiazepines was permitted if they were 
absolutely necessary, and if they had been continued during two or more months prior 
to baseline in stable daily dosages not exceeding 30 mg of diazepam or comparable 
dosages of other benzodiazepines,
-occasional use (i.e., three or less times weekly) of benzodiazepines in daily dosages 
exceeding 30 mg of diazepam or comparable dosages of other benzodiazepines. Use of 
benzodiazepines on the day of clinical assessment was not allowed before the 
assessment,
15) electroconvulsive therapy (ECT) within three months prior to baseline,
16) any clinically relevant abnormality detected during the physical examination or
laboratory screening tests that were likely to interfere with the conduct of the study.
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4.3 MAIN STUDY PROCEDURES 
4.3.1 GENERAL OUTLINE
Patients who complied with all selection criteria were enrolled to the trial and after a 
one-week single-blind placebo run period, they were randomly assigned to either 
mirtazapine 30mg or placebo quaque hora somni (QHS) in a double-blind fashion for
six weeks. After that, patients eligible and willing to participate entered the six week 
open-label phase, where they received mirtazapine 30mg QHS (Figure 1). 
4.3.2 DEMOGRAPHICS AND OTHER GENERAL SUBJECT CHARACTERISTICS
The following data were obtained from the patient and primary clinical documents:
• date of birth
• diagnosis (DSM-IV)
• time of onset of the illness
• date of onset of the current episode
• number of previous psychotic episodes
• date and reason of hospitalization (if appropriate)
• date and reason of possible drop-out
• history of antipsychotic medication use (what antipsychotics, in what dosages, and
for how a long time have they been used prior to the study).
4.3.3 EFFICACY ASSESSMENTS
Clinical efficacy was assessed with the PANSS (Kay et al., 1987), the CGI and CDSS 
(Addington et al., 1993). For evaluation of depressive symptoms the depression/anxiety 
factor of PANSS and the PANSS depression item were used. Subjective attitudes of the 
patients to the study medication were further assessed with the Patient Global 
Impression Scale (PGI, Guy, 1976).
Clinical assessments were performed at week –1 (screening), week 0 (baseline) and 
after 1, 2, 4, 6, 7, 8, 10, and 12 weeks of treatment.
4.3.4 SAFETY AND TOLERABILITY ASSESSMENTS
The FGA-induced extrapyramidal symptoms were evaluated with the SAS (Simpson & 
Angus, 1970) simultaneuously with the clinical assessments. Physical examination and 
laboratory tests (including complete blood count, fasting levels of glucose and total 
cholesterol) were performed at screening and at end-point. In addition to this the 
subjects were asked about any adverse events, while using the study medication.
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4.3.5 CONCOMITANT MEDICATIONS
The following medications were not allowed during the study:
1) Antidepressants other than the study drug (mirtazapine) as defined in this
protocol
2) Antipsychotics other than the patient’s pre-existing FGA(s)
3) Mood stabilizers
4) Regular (i.e. four or more times within one week) use of sumatriptan, naratriptan,
zolmitriptan or drugs with a similar mechanism of action. Even occasional use of these 
drugs was not allowed on the days of clinical assessments and before the assessments.
5) Buspirone or drugs with a similar mechanism of action
6) Benzodiazepines:
-regular use (i.e. four or more times weekly) of any benzodiazepines at any dosages 
were not allowed if they have not been started for the two or more last months prior to 
baseline (week 0) in stable dosages not exceeding 30 mg of diazepam or equivalent. The 
investigators will be encouraged to keep the regular benzodiazepine medication 
unchanged during the study. A decrease in dosages was, however, allowed due to ethical 
reasons, while an increase dosage was not allowed.
-occasional use (i.e. three or less times weekly) of benzodiazepines in daily doses
exceeding 30 mg of diazepam or equivalent was not allowed. Occasional use of 
benzodiazepines at any dosage was not allowed on the days of clinical assessments and 
before the assessments.
7) Zopiclon, zolpidem and zaleplon were permitted as hypnotics if necessary, in
dosages not exceeding recommendations of the manufacturer.
4.4 STATISTICAL METHODS
4.4.1 EFFICACY VARIABLES
The primary efficacy variables were the PANSS total scores. Secondary efficacy 
parameters included the PANSS subscale scores, number of responder	

20 % decline on the total and/or negative PANSS scores and/or those scoring much 
improved or very much improved on the CGI improvement item), CDSS and Simpson-
Angus Scale scores. The analysis was made on a Modified Intent-to-Treat (MITT) basis 
 		
	-therapy evaluations) with the last observation 
carried forward (LOCF). An observation was considered to be on-therapy if it occurred 
within 3 days of the patient’s final full dose of the study medication. 
Initial calculations indicated that 17 patients per treatment group would be required 
to guarantee power of 0.80 in detecting of difference (alpha=0.05) when comparing 
therapies (mirtazapine vs. placebo) with underlying success rate of 20 points decrease 
on the PANSS total score from the estimated initial score of 100 (SD 20). Since a 
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substantial drop-out rate was expected, the number of patients entering each treatment 
group was increased to 20.
4.4.2 STATISTICAL MODELS
Cross-sectional statistical differences between the study groups (between-group 
differences) were analyzed using an independent samples t-test for continuous variables 
and the chi-square test for categorical variables. Within-group changes in the efficacy 
variables over time were tested by the paired sample t-test. Post hoc type comparisons of 
the treatments were based on estimated marginal means when repeated measures 
ANOVA were used. Spearman correlation analysis was performed for calculations of 
correlations between measured values. Relationships between the changes in the 
metabolic parameters and PANSS-measured changes of psychopathology were analyzed 
using the linear regression model, which included changes in each of the PANSS 
(sub)scales as dependent variables and changes in body weight, fasting glucose and total 
cholesterol levels as independent variables.
Two-tailed p-values less than 0.05 were considered statistically significant. Analyses 
were performed using SPSS for Windows 19.0 software (SPSS Inc.).
4.4.3 DEFINED PATIENT SAMPLES FOR COMPARISONS
The primary comparisons were between the mirtazapine and placebo groups. Three 
patient samples were defined for the purposes of analysis. 
The safety sample comprised all patients who had received at least one dose of study 
medication, and had at least one post-dose safety assessment.
The primary sample was the “modified intent-to-treat” sample with the last 
observations carried forward (LOCF). This sample included all randomly assigned 
patients with at least one on-therapy evaluation.
The per-protocol sample comprised all patients in the intent-to-treat population who 
had completed 12 weeks of the study without a major protocol violation.
4.5 ETHICS
The present study was conducted in compliance with the current revision of the 
Declaration of Helsinki, Guideline for Good Clinical Practice (ICH_GCP) and with the 
current National Regulations in the Russian Federation Karelian Republic.
The study protocol was considered and approved by the Ethical Committee of the 
Karelian Republic and the local institutional review board before the beginning of the 
trial.
After a complete description of the study, a written informed consent was obtained 
from each patient. Patients were able to withdraw their consent at any time. Patients 
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were recruited only if add-on treatment was considered appropriate for them from a 
clinical point of view. 
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5 RESULTS
5.1 THE PATIENT POPULATION: CLINICAL AND 
DEMOGRAPHIC CHARACTERISTICS
5.1.1 THE DOUBLE-BLIND PHASE (STUDIES I, III AND IV): 
The recruitment of patients took place during the period from 1.9.2004 to 31.7.2007. 
Approximately two hundred patiens were selected for the pre-screening phase. Of these 
selected patients, we considered about 140 patients not to meet the inclusion criteria 
and about 90 patients declined to participate. Forty six patients were found to be 
eligible for the study and signed the informed consent. During the placebo run-in 
period, five withdraw the informed consent and, thus, 41 patients were randomized. One 
patient from the placebo group was withdrawn from the study immediately after the 
randomization, as the baseline assessments were not performed. Another patient from 
the same group was excluded due to a protocol violation (FGA dose lower than 200mg 
of chlorpromazine equivalent). Thus the modified intent to treat (MITT) population 
consisted of 39 patients: 20 of them formed the mirtazapine group and 19 formed the 
placebo group (Fig. 1). 
All other patients had a diagnosis of schizophrenia, except for one patient in the 
placebo group who had a diagnosis of schizoaffective disorder, depressive type. Patients 
received therapy with chlorprotixene (n=5), flupentixol (n=2), fluphenazine decanoate 
(n=8), haloperidol (n=14), haloperidol decanoate (n=10), levomepromazine (n=6), 
periciazine (n=2), sulpiride (n=1), trifluoperazine (n=13), zuclopentixol decanoate (n=5) 
or zuclopentixol (n=4). The majority of the patients in this study received 
polypharmacy, with the number of concomitantly used FGAs varying from two to four. 
These patients had received numerous antipsychotic trials during previous years of their 
treatment.
Baseline demographic and clinical characteristics, medication history or current FGA 
dosages did not significantly differ between the mirtazapine and placebo groups, with 
the exception of higher PANSS positive scores in the mirtazapine group (Table 2).
At baseline, there were no statistically significant differences between the groups for 
weight, blood pressure or any metabolic parameters (i.e., fasting glucose and 
cholesterol). 
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Table 2. Baseline demographics and clinical data of patients.
Mirtazapine (n=20) Placebo (n=19) Test statistics
Age, years 43.4 (9.24) 48.21 (9.68) t=1.59, p=0.121
Gender, males: n (%) 11 (55%) 9 (47.4%) 2=0.23, p=0.63
Inpatients: 11 (55%) 7 (36.8%) 2=1.29, p=0.26
Age at onset, years 23.45 (6.47) 24.11 (6.69) t=0.31, p=0.76
Duration of disease, 
years
19.95 (9.08) 24.95 (9.43) t=1.69, p=0.100
Number of previous 
psychotic episodes
7.85 (4.13) 6.71 (5.03) t=0.79, p=0.44
Current FGA dose,
CPZ equivalents, mg
330.75 (123.53) 316.58 (164.87) t=0.31, p=0.76
Number of previous
antipsychotic trials
8.50 (2.69) 8.11 (3.49) t=0.40, p=0.69
PANSS positive 22.15 (4.10) 18.89 (5.13) t=2.20, p=0.03
PANSS negative 30.90 (4.68) 29.26 (5.06) t=1.05, p=0.30
PANSS general 53.05 (6.20) 51.42 (8.65) t=0.68, p=0.50
PANSS total 106.10 (10.20) 99.58 (16.06) t=1.52, p=0.14
CGI 4.45 (0.61) 4.21 (0.42) t=1.43, p=0.16
SAS 12.05 (5.18) 10.00 (4.70) t=1.29, p=0.20
CDSS 5.00 (5.18) 4.5 (4.87) t=0.31, p=0.75
5.1.2 THE OPEN-LABEL PHASE (STUDY II)
Of the completers from the double-blind phase, 39 patients consented to participate in 
the open-label extension phase. Of these, 20 patients were previously treated with 
mirtazapine (further referred as the continuation group) and 19 patients were previously 
treated with placebo (further referred as the switch group). Two patients (both from the 
switch group) discontinued mirtazapine treatment during the open-label phase due to 
adverse events; i.e., excessive sedation (which emerged at week 7, n=1) or agitation, 
anxiety and aggressive behavior (which emerged at week 10, n=1). Due to a protocol 
violation, this same patient was excluded from the analysis, as in the double-blind phase 
of the study. The remaining continuation group patients (n=20) and switch group 
patients (n=16) were eligible for the MITT analysis. 
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Figure 1. Patients’ flow in the double-blind and open-label phases.
* same patient as in the double-blind phase, included at baseline of the open-label
phase.
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5.2 DOUBLE-BLIND PHASE (STUDIES I, III AND IV): THE 
MAIN FINDINGS IN WITHIN-GROUP AND BETWEEN-
GROUP COMPARISONS.
5.2.1 THE EFFECT OF MIRTAZAPINE ON POSITIVE AND NEGATIVE 
SYMPTOMS.
The double-blind phase results for the mirtazapine and placebo groups are presented in 
Table 3.
In the mirtazapine group, a statistically significant improvement in all PANSS 
subscales was registered. Treatment with placebo led to a slight improvement (3%) only 
in the PANSS negative subscale.
The effect size of d=1.00 (CI95% 0.34-1.67) on the PANSS total scores for clinical 
significance during the double-blind phase was observed. 
In the between-group comparison, mirtazapine clearly outperformed placebo on 
PANSS positive, negative and total subscales. On the PANSS general subscale, there was 
also a trend in favor of mirtazapine, which did not reach statistical significance. No 
comparisons in favor of placebo were revealed. In post hoc tests, the difference between 
treatments became evident at week 4.
There were four responders (20.0%) in the mirtazapine group and one responder 
(5.3%) in the placebo group (p=0.342).
5.2.2 THE EFFECT OF MIRTAZAPINE ON DEPRESSIVE SYMPTOMS.
The CDSS scores, the depression/anxiety factor of PANSS and the PANSS depression 
item score decreased significantly in the mirtazapine group (Table 3), while no 
significant changes were observed in the placebo group. The between-group comparison 
favored mirtazapine on the depression/anxiety factor of PANSS. On two other 
measures, a similar trend was noticed, but did not reach statistical significance. The 
same depression scores did not decrease in the placebo group. The changes in the CDSS 
scores, in the depression/anxiety factor of PANSS and in the PANSS depression item 
score were, correspondingly, 0.81 (SD=2.40, t=1.35, p=0.196), 0.75 (SD=2.02, t=1.49, 
p=0.158) and 0.06 (SD=0.93, t=0.27, p=0.79).
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5.2.3 THE EFFECT OF MIRTAZAPINE ON EPS
During the double-blind phase the severity of extrapyramidal symptoms (EPS), as 
measured by the SAS, decreased from 12.05 to 10.0 points (t=2.62, p=0.017) in the 
mirtazapine group, and from 10.0 to 9.58 points (t=0.69, p=0.501) in the placebo group. 
In the between-group comparison of changes, no statistically significant differences 
were noted between mirtazapine and placebo (t=1.64, p=0.112).
5.2.4 SAFETY AND TOLERABILITY OF MIRTAZAPINE ADD-ON TREATMENT IN 
THE STUDY POPULATION
5.2.4.1 Adverse effects during the double-blind phase
In the safety sample, 12 adverse events were registered with mirtazapine and 10 with 
placebo. In the mirtazapine group these were: hypersedation (n=3), weight gain (n=3), 
increased appetite (n=1), weakness (n=1), hypersedimentation (n=1), arrhythmia (n=1), 
uterine myoma (n=1), dizziness (n=1). In the placebo group these were headache (n=2), 
hypersalivation (n=1), weight gain (n=1), collapse (n=1), acute respiratory disease (n=1), 
nausea (n=1), agitation (n=1), conjunctivitis (n=1), sleep disturbance (n=1). None of 
these adverse events led to a withdrawal from the study.
5.2.4.2 Changes in metabolic parameters (Study IV) 
During the double-blind phase, there was a statistically significant increase in body 
weight and total cholesterol in the mirtazapine group (Table 4). A growth trend in both 
systolic and diastolic blood pressure was observed in the mirtazapine group, but this did 
not reach statistical significance. None of these parameters changed in the placebo 
group. 
In the between-group comparison of longitudinal changes, a statistically significant 
difference in weight, systolic blood pressure and total cholesterol was revealed (Table 4). 
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Table 4. Changes in weight, blood pressure and metabolic parameters in FGA-treated patients with 
schizophrenia during the 6 week double-blind treatment with add-on mirtazapine (n=20) or placebo (n=19). 
Parameter* 
Baseline Change, week 6 – week 0
Mirtazapine 
group
Placebo 
group
Mirtazapine 
vs. placebo 
group
Within 
mirtazapine 
group
Within 
placebo 
group
Mirtazapine 
vs. placebo 
group
Weight, kg 67.13 (5.97) 71.05 
(12.18)
t=-1.08
p=0.29
3.72
t=4.729
p<0.005
0.01
t=0.03
p=0.97
t=-4.38
p<0.005
Systolic 
blood 
pressure, 
mm.hg.
119.21 (10.17) 122.75 
(11.29)
t=-1.03
p=0.311
3.68
t=1.895
p=0.074
-2.63
t=-1.37
p=0.18
t=-2.31
p=0.03
Diastolic 
blood 
pressure, 
mm.hg.
76.32 (5.97) 77.00
(4.97)
t=-0.39
p=0.69
3.42
t=1.998
p=0.061
0.79
t=0.76
p=0.45
t=-1.32
p=0.19
Glucose, 
mmol/l.
4.96 (0.69) 4.98
(0.73)
t=-0.13
p=0.89
-0.15
t=-0.885
p=-0.387
0.06
t=0.31
p=0.76
t=0.83
p=0.41
Total
cholesterol,
mmol/l.
4.68 (0.99) 5.22 
(0.83)
t=-1.87
p=0.07
0.95
t=3.515
p=0.002
-0.2
t=-1.68
p=0.11
t=-3.83
p<0.005
*Data given as mean (sd).
5.3 DOUBLE-BLIND PHASE: THE RELATIONSHIPS BETWEEN 
CLINICAL, DEMOGRAPHIC AND LABORATORY 
PARAMETERS (STUDIES III AND IV).
5.3.1 RELATIONSHIPS BETWEEN IMPROVEMENT IN DEPRESSIVE SYMPTOMS 
AND OTHER CLINICAL DOMAINS OF SCHIZOPHRENIA.
In the mirtazapine group, the changes in the CDSS scores correlated positively with 
those in the PANSS positive, negative and total (sub)scales (Table 5). In the same group 
the changes in the PANSS depression/anxiety factor correlated positively with those in 
the PANSS positive, general and total (sub)scales. Changes in the PANSS depression 
item correlated positively with those in the PANSS general and total (sub)scales.
In the placebo group, changes in the CDSS and PANSS depression item correlated 
positively with those in the PANSS negative subscale.
48
Table 5. Correlations between changes in depressive symptoms and PANSS-measured clinical symptoms in 
FGAs-treated patients with schizophrenia during the 6-week double-blind treatment with add-on mirtazapine 
(n=20) vs. placebo (n=19).
Mirtazapine group Placebo group
Change in:  	

depression/
anxiety factor
	

depression 
item
 	

depression/
anxiety factor
	

depression 
item
	

positive
0.52** 0.51* 0.33 0.18 0.39 0.28
	

negative
0.49* 0.24 0.30 0.59* 0.27 0.65*
	

general
0.36 0.83** 0.54** 0.20 0.35 0.36
	

total
0.55** 0.77** 0.48* 0.46 0.51 0.51
	

*correlation is significant at the 0.05 level (Spearman’s rho).
**correlation is significant at the 0.01 level
5.3.2 RELATIONSHIPS BETWEEN MIRTAZAPINE-INDUCED 
METABOLIC CHANGES AND IMPROVEMENT IN CLINICAL 
PARAMETERS: RESULTS OF CORRELATION AND 
REGRESSION ANALYSES.
In the mirtazapine group, a change in total cholesterol level correlated negatively with 
changes in all (sub)scales of PANSS (Table 6). In the same group, the change in body 
weight correlated in the same manner with changes in the PANSS general scores and 
PANSS total scores, i.e. weight and total cholesterol increased with decreases in the 
PANSS scores. 
In the placebo group, a change in total cholesterol correlated negatively with changes 
in the PANSS positive subscale, and a change in glucose level correlated negatively with 
changes in the negative and general PANSS subscale scores.
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Table 6. Correlations between changes in metabolic parameters and changes in PANSS scores in FGA-treated 
patients with schizophrenia during the double-blind phase of an add-on treatment with mirtazapine vs. placebo.
Mirtazapine group (n=20)
 
 

pressure

 

pressure
 

	

positive
-0.39
p=0.11
-0.19
p=0.94
0.13
p=0.56
-0.08
p=0.74
-0.54
p=0.02*
	

negative
-0.19
p=0.44
-0.31
p=0.19
-0.16
p=0.50
0.04
p=0.08
-0.57
p=0.01
	

general
-0.50
p=0.03
0.03
p=0.89
0.09
p=0.7
0.40
p=0.08
-0.53
p=0.02
	

total
-0.48
p=0.04
-0.14
p=0.57
0.08
p=0.975
0.23
p=0.3
-0.63
p=0.003
Placebo group (n=19)
	

positive
-0.19
p=0.51
0.02
p=0.92
0.06
p=0.81
0.34
p=0.29
-0.42
p=0.05
	

negative
-0.26
p=0.39
-0.27
p=0.25
-0.14
p=0.56
-0.53
p=0.03
0.25
p=0.47
	

general
-0.42
p=0.08
-0.05
p=0.85
-0.8
p=0.76
-0.51
p=0.03
-0.05
p=0.78
	

total
-0.41
p=0.1
-0.19
p=0.43
-0.05
p=0.84
-0.39
p=0.06
-0.11
p=0.67
	

*Spearman rho is significant at the 0.05 level.
Linear regression analysis revealed that in the mirtazapine group changes in total 
cholesterol were associated with changes in all PANSS (sub)scales scores (Figure 2). 
Namely, an increase of total cholesterol by 1 mmol/L predicted a reduction of 1.7 points 
(r=0.72, p=0.03) in the PANSS positive, 1.8 points (r=0.73, p=0.004) in the PANSS 
negative, 3.5 points (r=0.83, p=0.005) in the PANSS general and 7 points (r=0.85, 
p=0.001) in the PANSS total scores. No other significant associations were found 
between the measured physical and metabolic variables and PANSS (sub)scale scores. 
In the placebo group, linear regression analysis did not reveal any statistically 
significant relationships between metabolic parameters and symptoms of psychosis.
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RESULTS
5.4 THE OPEN-LABEL PHASE: THE MAIN FINDINGS 
(STUDY II, III AND IV)
5.4.1 THE EFFECT OF MIRTAZAPINE ON POSITIVE, NEGATIVE AND 
DEPRESSIVE SYMPTOMS
In the continuation group, prolongation of mirtazapine treatment led to 
additional improvement in all PANSS (sub) scales (Table 7). The additional 
improvement was 10.8%, 13.8%, 8.1% and 11.2% for PANSS total, positive, 
negative and general scores, respectively.
In the switch group, a statistically significant improvement was registered 
in all PANSS (sub) scales. PANSS total scores decreased by 16.6%, and 
PANSS positive, negative and general scores dropped respectively by 20.3%, 
17.0% and 15.0%.
For the total population of the study (i.e., pooled continuation and switch 
groups), the effect size during the open-label phase was 0.94 (CI 95%=0.45–
1.43) as assessed by the PANSS total score. 
Table 7. Changes in PANSS-measured clinical parameters during the open-label add-on
treatment with mirtazapine (n=20) vs. placebo (n=19).
Within-group change, week 6-12,
mean (SD)
Between-group change,
week 6-12,
continuation vs. switch groupContinuation group Switch group
PANSS total 10.00 (7.32)
t=6.11
p<0.001
15.63 (8.17)
t=7.65
p<0.001
t=2.18
p=0.04
PANSS positive 2.50 (2.37)
t=4.71
p<0.001
3.68 (2.06)
t=7.17
p<0.001
t=1.58,
p=0.12
PANSS negative 2.20 (2.50)
t=3.93
p<0.001
4.68 (3.11)
t=6.02
p<0.001
t=2.66
p=0.01
PANSS general 5.30 (3.87)
t=6.13
p<0.001
7.25 (4.01)
t=7.24
p<0.001
t=1.48
p=0.15
During the open-label phase, depressive symptoms measured with CDSS 
and the PANSS depression item decreased with statistical significance in 
both treatment groups. In the continuation group, the mean CDSS score 
decreased by 1.45 points (SD=1.67, t=3.88, p=0.001), the depression/anxiety 
factor of PANSS decreased by 1.20 (SD=1.51, t=3.56, p=0.002) and the 
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PANSS depression item decreased by 0.45 points (SD=0.60, t=3.3, 
p=0.004). In the switch group, depression measures also began to improve. 
By the endpoint, the mean CDSS score decreased by 2.75 (SD=3.99, t=2.76, 
p=0.02), PANSS depression/anxiety factor by 3.13 (SD=1.78, t=7.0, p=0.001) 
and the PANSS depression item by 0.88 (SD=1.02, t=3.4, p=0.004).
In the between-group comparison of changes, only the depression/anxiety 
factor improved significantly more in the switch group (t=3.50, p=0.002), 
while no significant differences were found in the two other parameters. 
Changes in the CDSS scores were approximately of the same magnitude 
for the switch group in the open-label phase, and for the continuation group 
in the double-blind phase (2.75 and 2.6 points, respectively).
Correlation analysis did not reveal any significant relationships between 
changes in the depression scores and those from the PANSS (sub)scales’ 
scores for either group.
5.4.2 THE EFFECT OF MIRTAZAPINE ON FGA-INDUCED EPS DURING 
THE OPEN-LABEL PHASE
During the open-label phase, SAS scores decreased by 2.60 points (SD=1.98, 
t=5.86, p<0.001) in the continuation group, and decreased by 3.69 points 
(SD=2.87, t=5.14, p<0.001) in the switch group.
5.4.3 SAFETY AND TOLERABILITY OF MIRTAZAPINE DURING THE 
OPEN-LABEL PHASE: THE INFLUENCE OF MIRTAZAPINE 
TREATMENT ON WEIGHT AND METABOLIC PARAMETERS
The total number of adverse events (AE) during the open-label phase was 11. 
Three of these events (i.e., acute respiratory disease, weight gain and 
headache, n=1 for each AE) were registered in the continuation group and 
eight were registered in the switch group (i.e., headache (n=2), weight gain 
(n=2), excessive sedation (n=2), increased appetite (n=1) and marked 
agitation (n=1)). Agitation, which developed in one patient in the 
continuation group, led to withdrawal from the study in week 10. No serious 
AEs were registered during the open-label phase.
In the continuation group, there were no significant changes in weight, 
blood pressure or metabolic parameters.
In the switch group, weight increased by 2.72 kg (SD=3.47, t=-3.04, 
p=0.009) and cholesterol increased by 0.49 mmol/l (SD=0.97, t=-2.09, 
p=0.05). No changes in other measured parameters were registered. In the 
between-group comparison, no statistically significantly differences were 
found between the treatment groups. Weight gain in the switch group was 
approximately the same during the open-label phase as in the continuation
group during the double-blind phase.
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5.5 BOTH PHASES: CHANGES IN CLINICAL 
PARAMETERS DURING MIDDLE-TERM (12 WEEKS) 
VERSUS SHORT-TERM (6 WEEKS) OF ADD-ON
TREATMENT WITH MIRTAZAPINE (STUDY II)
Middle-term treatment (the continuation group) led to an improvement of 
27.7%, 18.7%, 20.0% and 21.6% in the PANSS positive, negative, general and 
total scale scores, respectively. The between-group comparison of a 
longitudinal change revealed a significant difference in favor of the middle-
term mirtazapine treatment, but only for the PANSS positive scores (t=2.31, 
p=0.027). No differences in other clinical parameters were found. 
The number of responders for both phases was twelve in the continuation 
group and seven in the switch group. No statistical differences were found in 
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6 DISCUSSION
6.1 THE MAIN FINDINGS
This study was designed to explore the possible influence of mirtazapine 
added to ongoing treatment with different FGAs on the main clinical 
domains of schizophrenia. The influence of mirtazapine on FGA-related EPS 
was also studied. In addition, this study focused on safety and tolerability 
aspects of mirtazapine treatment in schizophrenia. As compared to the 
previous studies of mirtazapine add-on treatment in schizophrenia, the 
present study used a wider range of assessments, especially in regard of 
depressive symptoms. This study was the first to analyse the correlations 
between the effects of mirtazapine on positive and negative symptoms and its 
antidepressive effect. This study was also the first to report the relationships 
between clinical effects of mirtazapine and its metabolic influences.
The study population consisted of patients who suffered from a prolonged 
disease and had a previous history of insufficient response to a number of 
antipsychotic trials. At the stage of enrollment, study patients were at a 
relatively stable stage of their disease, and their FGA treatment had remained 
unchanged during a period of six previous weeks. Patients were highly 
symptomatic in both mirtazapine and placebo groups.
This study was the first to report a statistically significant favorable effect 
of mirtazapine-FGA combination on a wide range of clinical parameters. 
During the double-blind phase, clear-cut differences in all PANSS (sub)scales 
favored mirtazapine treatment in comparison with placebo in both the within 
group and between group analyses. A large effect size of d=1.00 (CI95% 0.34-
1.67) on the PANSS total scores for clinical significance was observed. In an 
previous RCT by Berk et al. (2001) the effect-size on PANSS negative scores 
was 0.28 (-0.36 – 0.92).
Augmentation with mirtazapine also alleviated FGA-induced EPS, and led 
to decreases in depression scores. Treatment with mirtazapine raised weight 
and cholesterol levels, which being a negative change from the viewpoint of 
general health, was though directly correlated with the degree of clinical 
improvement.
In the open-label phase, patients who switched to mirtazapine treatment 
demonstrated clinical improvement in the same manner as their 
mirtazapine-treated counterparts in the double-blind phase. Prolonged (12 
weeks) treatment with mirtazapine led to more prominent improvements in 
clinical parameters than short-term (6 weeks) treatment.
Mirtazapine was in general well-tolerated, with no serious adverse events 
during the study, and only one dropout due to a worsening of the patient’s 
mental condition.
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6.2 EFFICACY OF ADD-ON MIRTAZAPINE IN 
SCHIZOPHRENIA: PANSS-MEASURED CLINICAL 
PARAMETERS
In the double-blind phase of the study, a statistically significant 
improvement was registered in regard to both negative and positive 
symptom domains. The difference in favor of mirtazapine was found both in 
within-group and between-group analyses. Improvement in negative 
symptoms due to mirtazapine add-on treatment have been reported in 
several RCTs. Three of the four RCTs conducted so far have demonstrated 
the superiority of mirtazapine over placebo on PANSS negative subscale 
scores when added to haloperidol (Berk et al., 2001), clozapine (Zoccali et al., 
2004) and risperidone (Abbasi et al., 2010). The magnitude of the negative 
symptoms reduction in the RCT of Berk and co-authors was more significant, 
with a 42% drop in PANSS negative subscale scores. This difference could be 
explained by a less chronic patient population (mean age 29.5 years vs. 43.8 
years in our study), not selected for signs of treatment resistance, which 
included patients with both first episode and recurrent illness. The studies by 
Zoccali and co-authors, and by Abbasi and co-authors, also reported results 
that favored mirtazapine add-on treatment. The results from the present 
study support these earlier findings, as we also found a substantial reduction 
in negative symptoms. However, our data differ from these earlier reports in 
terms of the newly found effect on positive psychotic symptoms. This new 
phenomenon could be explained by several factors; e.g., differences in 
antipsychotic medication in terms of both drugs and their dosages (in our 
study, a number of different FGAs were used in moderate dosages), study 
population (patients with a predominantly chronic course of the disease and 
signs of treatment resistance, not especially selected for negative symptoms) 
and relatively high retention rates. Indeed, according to a meta-analysis of 
Rabinowitz et al. (2009), drop-out rates in RCTs with antipsychotics vary 
from 19.3 to 75.5%, while in the present study the drop-out rate was only 
7.5%.
In a RCT by Berk and co-authors (2009), no favorable effects of add-on 
mirtazapine in schizophrenia were found. However, in that study 
mirtazapine was added to treatment with SGAs, mostly clozapine, which 
definitely makes a direct comparison of these studies impossible.
Patients in the switch group, demonstrated a marked degree of 
improvement that was comparable the improvement seen in their 
counterparts from the continuation group during the double-blind phase. 
This tendency was seen in all the measured parameters, thus providing more 
evidence of mirtazapine’s favorable effect on schizophrenia symptoms. 
In the continuation group, treatment with add-on mirtazapine for six 
additional weeks resulted in a further reduction of all PANSS (sub)scales 
scores. In between-group comparison the difference was statistically 
significant only in the PANSS positive subscale. During the 12-week 
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treatment, there were more responders in the continuation group than in the 
switch group. Thus, prolonged add-on treatment with mirtazapine can be 
beneficial, at least in regard to positive symptoms. This finding is also novel, 
as in earlier studies (all of which were of a shorter duration – from six to 
eight weeks) no similar relationships between the efficacy and duration of 
treatment were reported.
The effect of mirtazapine on schizophrenia symptoms, as elucidated in the 
present study, may be explained by its receptor profile. Regarding the 
influence on negative symptoms, there are several possible mechanisms that 
may contribute to mirtazapine’s beneficial effect. The first is the blockade of 
5-HT2a receptors – a common characteristic of both mirtazapine and SGAs, 
which is also evidently responsible for the better efficacy of the SGAs on the 
negative symptomatology of schizophrenia (Meltzer, 2012). In this sense, the 
addition of mirtazapine to FGAs imitates the SGAs’ receptor profile, which 
was a main hypothesis in this study. Blockade of central 5-HT2a receptor 
results in a number of effects on dopaminergic activity in the mesocortical, 
mesolimbic, and nigrostriatal areas of the brain. It has been demonstrated in 
several preclinical studies that a combined 5-HT2a and D2 receptor inhibition 
may have a stimulating effect on the mesocortical pathway of the frontal 
cortex, thus increasing dopamine in this area (Volonte et al., 1997, Kuroki et 
al., 1999, Rollema et al., 2000). This effect is known to be selective, i.e. no 
concurrent stimulation of dopaminergic neurotransmission in the striatum 
occurs (Bonaccorso et al., 2002). Furthermore, Liegeois and co-authors 
(2002) based their dose–response relationship study of haloperidol 
combined with the highly selective 5-HT2a antagonist M100907. The idea 
being that FGAs coupled with 5-HT2A antagonists may promote dopamine 
release in mPFC, with only a slight impact on nigrostriatal function. The 
result was that M100907 did potentiate the ability of low dose (0.01–0.1 
mg/kg) haloperidol to increase dopamine release in mPFC, whereas no such 
effect were observed with higher (0.3–1.0 mg/kg) dose of haloperidol 
(Liegeois et al., 2002). Dopamine deficiency in the mPFC is known to 
underlie the negative and cognitive symptoms of schizophrenia (Howes and 
Kapur, 2009), and thereby such a drug combination may lead to better 
treatment outcomes having a diminished risk for EPS (Meltzer et al., 2003).
This hypothesis was encouraged from an earlier study by Duinkerke and 
co-authors (1993), where adjuvant treatment with ritanserine, a pure 5HT2
antagonist lacking antidepressive effects, led to an alleviation of negative 
symptoms in haloperidol-treated schizophrenia patients. Some additional
evidence supporting this theory came also from a study with mianserin – 
another antidepressant with a similar receptor profile, blocking of 5-HT2, 5-
HT3 and alpha-2 adrenoreceptors (Hayashi et al., 1997). In that study, 
adjuvant therapy with mianserin led to an improvement of negative 
symptoms in FGA-treated schizophrenia patients. This evidence, however, 
remains controversial, as two other studies failed to replicate this result 
(Shiloh et al., 2002, Poyurovski et al., 2003).
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Mirtazapine’s indirect agonist effects on 5-HT1a receptors may also 
underlie its efficacy on negative symptoms. The 5-HT1a receptor may be 
involved in the mechanisms of negative and cognitive symptoms of 
schizophrenia (Kishi et al., 2011). In a preclinical study by Ichikawa and 
Meltzer (2000), a 5-HT1a agonist was shown to stimulate dopamine release in 
the prefrontal cortex and to enhance the effects of D2 antagonists. In clinical 
studies, pure 5-HT1a agonists improved schizophrenia-related cognitive 
deficits (Sumiyoshi et al., 2001, Sumiyoshi et al., 2007). Direct or indirect 
agonism of 5-HT1a receptors is a common characteristic for the majority of 
SGAs (Meltzer, 2012) and is, along with 5-HT2 blockade, responsible for their 
better efficacy on negative symptoms, compared to FGAs.
Another possible explanation for add-on mirtazapine’s efficacy on 
negative symptoms is its 5-HT3 blocking properties. The role of 5-HT3
receptors in the pathophysiology of negative symptoms was already proposed 
in early 1990s (Costall and Naylor, 1992). Research evidence supporting this 
theory first came from a clinical study by Zhang and co-authors (2006), in 
which the 5-HT3 blocking agent ondansetron added to haloperidol improved 
negative symptoms, general psychopathology and cognitive functions in 
patients with chronic schizophrenia. No further research on this topic was 
reported after that, so this finding can be only considered as preliminary.
Interestingly, in a recent preclinical study by Masana and co-authors 
(2012), mirtazapine selectively increased dopamine function in the prefrontal 
cortex of rodents. Decreased dopamine activity in that area seems to be one 
of the key neurotransmitter abnormalities that underlies the negative 
symptoms in schizophrenia. This suggests another possible mechanism of 
mirtazapine effect on negative symptoms, which was elucidated in the 
present study.
It is challenging to outline possible explanations for the favorable effect of 
mirtazapine add-on treatment on positive symptoms in schizophrenia. 
Indeed, the antipsychotic effect of current medications has been mainly 
attributed to D2 receptor antagonism (Yilmaz et al., 2012). There is, however, 
intriguing data from both preclinical and clinical studies that indicate a 
possible useful role for alpha-2-adrenoreceptor inhibition in antipsychotic 
efficacy. In a preclinical study (Wadenberg et al., 2007), the alpha-2
antagonist idazoxan enhanced the therapeutic effect of haloperidol and 
olanzapine, and also reversed haloperidol-induced catalepsy. This result was 
supported by another preclinical study (Marcus et al., 2010), where idazoxan 
enhanced the efficacy of risperidone and facilitated both dopaminergic and 
glutamatergic neurotransmission in the prefrontal cortex. Earlier, in a 
clinical trial by Litman and co-authors (1996), idazoxan added to ongoing 
fluphenazine therapy produced clinical improvement comparable to that of 
clozapine in patients with schizophrenia. It has thus been proposed that 
alpha-2 inhibition enhances the antipsychotic effects of D2 blockade (Choi et 
al., 2009). 
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According to a report of preclinical data (Berendsen et al., 1998), 5HT1A
receptor agonism may also contribute to enhancing the effect of 
antipsychotics, although clinical support for this assumption is still lacking. 
An inhibition of histamine H1 receptor, a common mechanism of action for 
mirtazapine and clozapine, may also contribute to the antipsychotic effect of 
mirtazapine (Mancama et al., 2002). 
The pathophysiology of schizophrenia includes, among numerous other 
mechanisms, neurodegeneration and impaired neurogenesis (Inta et al., 
2011). A growing body of evidence suggests that antidepressants may 
reactivate neuroplasticity (Castren and Rantamäki, 2010), which mechanism 
may provide a number of potential pharmacological contributors to the 
improved efficacy and better treatment outcomes in schizophrenia. 
According to both preclinical (Rogoz et al., 2005) and clinical data (Katsuki 
et al., 2012), mirtazapine appears to induce brain-derived neurotrophic 
factor (BDNF) gene expression and subsequently to raise BDNF serum levels, 
which points to its putative neuroprotective properties. 
Interestingly, in a study by Katsuki and co-authors (2012) the raise in 
BDNF levels in responders to mirtazapine was observed during the first four 
weeks of treatment. This corresponds to the results of the present study, 
where statistically significant difference between mirtazapine and placebo 
started to be evident after four weeks of treatment. This suggests a possible 
role of enhanced neurogenesis in the clinical effects of mirtazapine. This, in 
turn, may eventually be of substantial benefit in the treatment of 
schizophrenia.
Mirtazapine is metabolized in part by the cytochrome P-450 (CYP) 2D6 
liver enzyme (Dodd et al., 2001). Being a very weak inhibitor of the CYP-
isoenzymes, mirtazapine is apparently not involved in the pharmacokinetic 
interactions of antipsychotics (Spina et al., 2008). Thus, its additional 
antipsychotic effect cannot be explained by an increase in the serum levels of 
the concomitantly used FGA.
6.3 EFFICACY OF ADD-ON MIRTAZAPINE IN THE
TREATMENT OF DEPRESSION IN SCHIZOPHRENIA
In the double-blind phase of the present study depression scores measured 
by CDSS, depression/anxiety factor of PANSS and PANSS depression item 
decreased with statistical significance in the mirtazapine group, but not in 
the placebo-group. 
The lack of a statistically significant difference favoring mirtazapine over 
placebo could have resulted the initial depression scores being relatively low 
in both groups, which has been found in earlier studies with chronic 
schizophrenia (Lancon et al., 2001, ). It is apparent that showing the 
antidepressive effect of mirtazapine in this particular population would 
require a separate study with more severe criteria for depressive symptoms.
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The present study considerably deviates from previous RCTs that 
investigated the putative efficacy of mirtazapine on depression in 
schizophrenia. In the study by Berk and co-authors (2001), haloperidol-
treated patients with schizophrenia also showed a noticeable improvement in 
depression scores, due to mirtazapine treatment, but these changes did not 
differ from the placebo group. A possible explanation for this difference in
antidepressive effect is a less stable patient sample in the present study and, 
secondary to this, a phenomenon known as “regression to the mean”. The 
limited sample size in the study of Berk et al (2001) may also include a risk 
for type II error. In a more recent study by Berk and co-authors (2009), add-
on mirtazapine did not improve symptoms of depression in SGA-treated 
schizophrenia. Actually, it has been proposed earlier that SGAs may improve 
depressive symptoms on their own in schizophrenia, even when used as 
monotherapy, thus making the potential effect of add-on treatment with 
antidepressants negligible or even unnecessary (Tollefson et al., 1999, 
Leucht, 2012). This might also be true for clozapine, as reported in a RCT by 
Zoccali and co-authors (2004) of add-on treatment with mirtazapine, which 
did not lead to an improvement in the depressive symptoms of clozapine-
treated schizophrenia. In addition, it should be noted that none of the above 
listed RCTs was specifically designed as a depression study, which can be 
seen, for instance, in the scarce set of depression measuring instruments 
(e.g., only the depression factor extracted from the BPRS was included in a 
study of Zoccali and co-authors). 
In the open-label phase of the present study, depressive symptoms 
continued to improve in the continuation group, with comparable changes in 
the switch group de novo. By the end-point, the CDSS scores decreased to a 
level lower than the threshold of three points for depression diagnosis 
(Addington et al., 1996) in both groups. Thus, it can be assumed that a period 
of six weeks may be enough to obtain the desirable antidepressive effect of 
mirtazapine in schizophrenia.
In the present study, the changes in CDSS, depression/anxiety factor of 
PANSS and the PANSS depression item for the mirtazapine group 
demonstrated several inconsistent direct correlations with desirable changes 
in PANSS scores during the double-blind phase. This finding makes it 
partially unclear whether or not the observed improvement in depressive
scores registered in the present study was in fact due to a specific 
antidepressive effect of mirtazapine, or some non-specific halo effect of the 
global improvement. However, no reverse correlations were found; i.e., 
improvement in depressive scores was not accompanied by a decline in other 
symptom clusters. A worsening of psychosis due mirtazapine treatment was 
seen in one case in the present study, while in the majority of patients 
mirtazapine improved positive symptoms.
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6.4 EFFICACY OF ADD-ON MIRTAZAPINE IN
ALLEVIATING FGA-INDUCED EPS
In this study, improvement on SAS-measured EPS was registered in the 
mirtazapine group, but not in the placebo group. A between-group 
comparison did not, however, yield any statistically significant differences. 
This finding might be due to the FGA dosages that varied from low to 
moderate in the present study. This could have resulted in initially low SAS 
scores, which might have reduced the possibility for a noticeable change. One 
contributing factor to this could be the current trend to use lower doses of 
FGAs to prevent the EPS, which is important when considering the treatment 
safety. 
Evidence from earlier studies that evaluated the efficacy of mirtazapine on 
antipsychotic-induced EPS remains controversial. In the study by Berk and 
co-authors (2001), mirtazapine was unable to outperform placebo in terms of 
its efficacy on haloperidol-related EPS. In that study, however, patients 
treated with add-on placebo also suffered from EPS and received 
anticholinergic medicines more frequently than patients receiving add-on 
mirtazapine. Similarly, in a study of Abbasi and co-authors (2010), 
adjunctive mirtazapine did not improve risperidone-induced EPS. There 
exist, however, two positive studies (Poyurovski et al., 2003, Poyurovski et 
al., 2008) in which add-on mirtazapine improved both SAS and BAS scores 
in patients treated with different FGAs and SGAs. Additional support comes 
from a recent preclinical study by Tatara et al. (2012), where mirtazapine 
attenuated haloperidol-induced EPS, while TCAs and SSRIs demonstrated 
opposite effect. 
The influence of mirtazapine on EPS-symptoms is presumably associated 
with its 5-HT2 blocking properties. In earlier preclinical studies, the 
blockade of 5-HT2A/2C receptors has been shown to attenuate EPS, which is 
further related to the blockade of striatal D2 receptors (Meltzer and Massey, 
2011, Ohno, 2011). This theory is also supported by studies with ritanserin, a 
potent 5-HT2A/2C blocker, which improved antipsychotic-induced EPS, both 
under preclinical (Tatara et al., 2012) and clinical conditions (Akhonzadeh et 
al., 2008). The same mechanism is plausibly associated with the lesser risk of 
EPS in SGAs, which are less potent D2 blockers than FGAs and also 5-HT2
blockers (Meltzer, 2012).
6.5 SAFETY AND TOLERABILITY OF MIRTAZAPINE 
ADD-ON TREATMENT IN SCHIZOPHRENIA
Mirtazapine was well tolerated during both study phases. The most frequent 
adverse effects were weight gain, increased appetite, and excessive sedation. 
A mirtazapine-provoked adverse effect led to discontinuation from the study 
in only one case. The other adverse effects were infrequent, mild and 
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transient. In general, the frequency and nature of mirtazapine adverse effects 
corresponded with the those described in major depression studies (Anttila
and Leinonen, 2001).
Besides the general tolerability issues of mirtazapine treatment, the 
present study also explored the relationships between metabolic effects and 
clinical efficacy of mitrazapine. As expected, mirtazapine caused weight gain 
and an increase in total cholesterol during the double-blind phase. These 
results are in concordance with earlier findings from studies on major 
depression (Thase et al., 2001), in which mirtazapine also increased both 
body weight and total cholesterol. Similar to prior reports (Montgomery, 
1995), mirtazapine did not cause any significant changes in fasting glucose 
levels.
Furthermore, one of the main findings of this study was that the increase 
in total cholesterol level in mirtazapine-treated patients was directly 
associated with the clinical improvement. In an RCT by Procyshyn and co-
authors (2007), the clozapine-related increase in serum lipids was also linked 
with the improvement in psychopathology. The difference between these 
findings is, that in their study the increased cholesterol level was associated 
only with an improvement in PANSS negative subscale scores. At the same 
time, the decrease in PANSS total scores correlated with an increase in serum 
triglycerides, while no associations were found between the increase in 
serum lipids and improvement on either PANSS positive or PANSS general 
scores. In a secondary analysis of the CATIE patient sample, Hermes et al. 
(2011) did not reveal significant associations between lipid parameters (i.e., 
cholesterol and triglyceride) and change in PANSS scores. However, the 
range of antipsychotics used in CATIE did not include clozapine, medication 
with perhaps the most evident relationship between its clinical efficacy and 
the metabolic effects (Procyshyn et al., 2007). The present study did not 
reveal any relationships between body weight gain and favorable changes in 
psychopathology, which has previously been reported with antipsychotics 
(Meltzer et al., 2003, Ascher-Svanum et al., 2005, Hermes et al., 2011). 
Clozapine (Lieberman et al., 2003) and olanzapine (Asenjo Lobos et al., 
2010) have consistently demonstrated better efficacy than some other 
antipsychotics with less noticeable metabolic adverse effects. A mechanism 
for the assumed relationships between lipid metabolism, psychopathology of 
schizophrenia and mechanism of action for antipsychotic drugs remains 
obscure. There is some evidence that low cholesterol levels can be associated 
with maladaptive behaviors; i.e., aggression (Golomb, 1998), suicide and self-
aggression (Muldoon et al., 1993). It has been proposed that a lowering of 
serum cholesterol levels may influence the composition of neuronal 
membranes with a consequent attrition of 5-HT receptors (Procyshyn, 2007). 
This may, in turn, contribute to an insufficient suppression of aggressive 
behavior and, according to some recent data, also contribute to the 
phenomenon of treatment-resistance in schizophrenia (Stone et al., 2010). 
Another mechanism that may possibly explain the relationship between 
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metabolic and psychotropic properties of mirtazapine, is an existing 
association between 5HT2-antagonism and insulin sensitivity. This 
phenomenon is thought to be associated with hypercholesterolemia and 
other forms of dyslipidemia (Bonora et al., 1998). In an RCT by Gilles and co-
authors (2005), ketanserin, an agent with 5-HT2-antagonist properties, 
demonstrated ability to impaire insulin sensitivity. Therefore the clinical 
effects of mirtazapine can in part be explained by each of the aforementioned 
mechanisms;,i.e. changes in lipid levels and blockade of serotonin receptors. 
Similarly to clozapine, mirtazapine also inhibits histamine-H1 receptors. This 
effect may not only contribute to the metabolic changes, but also be involved 
in the modulation of certain pathophysiological processes in schizophrenia 
(Mancama et al., 2002).
While probably lacking in antipsychotic efficacy itself, mirtazapine shares 
several metabolic side effects with the most effective antipsychotics, which 
may be at least some marker of its synergistic efficacy in impoving positive 
psychotic symptoms.
As a candidate for effective adjunct treatment of schizophrenia (Phan et 
al., 2011), mirtazapine increases body weight and serum cholesterol level –
both established to be serious risk factors for cardiovascular diseases. This 
observation dictates a need for a thorough evaluation of the pros and cons of 
this therapy in each individual case.
6.6 MAIN LIMITATIONS OF THE STUDY
The main limitation of the present trial was its small sample size, which may 
have adversely affected the statistical power of findings for secondary 
analyses. This weakness may, however, be compensated by the fact that the 
measured changes were large in magnitude and consistent with the wide 
range of different clinical parameters. Another limitation was the open-label 
design of the extension phase, which raises the question as to whether or not 
the observed favorable changes might be a result of a placebo effect or a 
spontaneous fluctuation of the disease (a so-called “regression to the 
means”). This does not appear very likely, because in the present study the 
changes in the measured parameters were essentially similar for the switch 
group in the extension phase as for the continuation group in the double-
blind phase. This perspective might better reflect the specific clinical effect of 
the study drug, rather than the influence of non-pharmacological factors.
Several limitations of the present study were connected to the 
characteristics of the patients’ population. First, the criterion requiring the 
presence of a stable period before enrollment to the study, led to limiting the 
study population to predominantly chronically or subchronically ill patients. 
This limitation makes it difficult to extrapolate our results to patients in 
acute stage of schizophrenia, Second, the present study was initially planned 
to be possibly close to “real-life” conditions, which resulted in heterogenity of 
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the study population, in terms of both anipsychotics used and of the duration 
of the disease. On the other hand, the above mentioned similarity of our 
patients’ population to the ones often met in real-life circumstances, can be 
considered as its strength.
For the depression branch of the study, the limitation was that the 
patients were not specifically selected for depression symptoms. This could 
be seen in the low depression scores at baseline, which initially means a 
limited potential for change. Due to this fact, the results gained in this study 
regarding the antidepressive effect of mirtazapine in schizophrenia should be 
interpreted with some caution.
The analysis of metabolic parameters was limited in the present study to 
fasting glucose and total cholesterol, while evaluations of other potentially 
important parameters (for instance, a broader panel of lipid parameters, e.g. 
LDL and HDL, body composition, leptin, insulin resistance index) were not 
conducted. 
A strength of the present study is that the patients’ population was 
presented with initially high PANSS scores, which makes it possible to 
extrapolate is results to patients with difficult-to-treat schizophrenia. 
Another strength is that patients were investigated using a wide range of 
widely approved and validated clinical scales. The present study included an 
RCT phase, which makes its results reliable from the viewpoint of the 
evidence-based medicine. In the present study the drop-out rate was very low 
which also improves the realibility of the results. 
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7 CONCLUSIONS AND FURTHER 
IMPLICATIONS
In schizophrenia with suboptimal response to the FGAs, adjunctive 
mirtazapine appears to improve negative and depressive symptoms and to 
alleviate FGAs-induced extrapyramidal side effects. Moreover, add-on 
mirtazapine can also improve positive symptoms – to the best of the auhtor’s 
knowledge, an effect never observed earlier for any antidepressant. The 
improvement in positive and negative symptoms may be independent on the 
antidepressive effect. The background of the additive efficacy is unknown but 
it may result from the atypical mechanism of action of mirtazapine – an 
inhibition of a certain combination of receptors (instead of inhibition of 
transporters as for the vast majority of other antidepressants).
As in unipolar depression, also in schizophrenia mirtazapine treatment 
causes body weight gain and an increase in the serum cholesterol levels. The 
metabolic changes, unwanted as such correlate, however, with improved 
psychopathology in a fashion, observed earlier for clozapine and some other 
SGAs.
These observations may have not only theoretical implications but, if 
confirmed in larger and longer studies affect current practices – an add-on 
mirtazapine trial may become a worthwhile option before switching to 
clozapine.
Further studies should focus on mirtazapine-SGA combinations, FGAs-
mirtazapine-combinations vs. switch to SGAs, include schizophrenia patients 
with prominent depression, and comparison with clozapine.
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APPENDICES
APPENDIX I. INFORMATION FOR A PATIENT AND
INFORMED CONSENT (ENGLISH VERSION).
Information for a patient.
Dear .....................................................................................
You are invited to participate in a study “Efficacy of add-on mirtazapine 
on the clinical and neuropsychologic parameters in schizophrenic patients 
treated with conventional antipsychotics – a double-blind placebo-controlled 
trial with an open-label extension phase”. This study is a collaborative 
scientific project of Russian and Finnish researchers. Please read this form 
and ask any questions you may have before you agree to be involved into the 
study.
The purpose of the study.
During this study, a medicine called mirtazapine will be added to you 
current treatment. Mirtazapine is an antidepressant which has been 
extensively and for a long time used in clinical practice in the majority of the 
European countries, in the US and Canada, as well as in Russia. The main 
indication for the use of mirtazapine is depression (long-lasting and 
profound decrease of mood and interest to life, fatigue, feeling of apathy, 
weakness, sleep and appetite disturbances). The disease you are suffering 
from is often accompanied to some extent with depressive symptoms, and 
additional use of antidepressants is common in the clinical practice. The 
mechanism of action of mirtazapine differs from that of the most part of 
other antidepressants. This difference supposes that this medicine is able to 
not only alleviate the depressed mood symptoms, but also make your current 
medication more effective. It can also decrease possible side effects of your 
basic medication, such as unpleasant feelings in the muscles, tremor, 
irritability, feeling of rigidity or weakness, or concentration difficulties. The 
addition of mirtazapine will probably enable decrease of the dosage of your 
basic medication. Supposedly, some properties of mirtazapine will improve 
the thought process, attention and memory, and increase your general level 
of functioning. The study you are invited to participate in will make the 
preliminary information, which the above assumptions are based upon, more 
accurate.
How the study will be conducted.
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At the first 6 weeks of the study, after the appropriate and comprehensive 
medical examination of your health, you will be prescribed a new medication 
– either mirtazapine, or the so-called ‘placebo’ – medicine, which looks like 
mirtazapine but doesn’t contain any pharmacologically active substances. 
Neither you, nor your doctor will know which medicine you will receive, but 
you may be provided with this information as soon as the whole study is over, 
i.e., when all the patients have completed their participation in it, and the 
data received during the study have been analyzed. During the second 6 
weeks placebo will not be administered, and all patients will receive 
mirtazapine. Mirtazapine will be administered in a recommended effective 
dose, once daily at the night time. The capsules or tablets must be swallowed 
wholly, ungrinded and unchewed.
You physician will possibly decrease the dosage of your basic medication 
in the second period of the study. Altogether, you will receive the study 
medication during 12 weeks (about 3 months). 
Procedures of the study.
During the study your physician will examine you with certain regularity 
– in total, 10 assessments of your mental and physical health will be 
performed. These visits of your physician may differ from the ordinary 
assessments that you are used to. They may include psychiatric and 
psychological testing (sometimes rather time consuming) and clinical and 
laboratory tests, such as ECG, blood and urine analyses.
Potential risk due to the participation in the study.
As all effective medicines, mirtazapine can cause side effects in some 
patients, such as dry mouth, sleepiness, increase of appetite and body weight. 
However, these symptoms are rare, usually mild and most often disappear 
without any specific intervention during the continuation treatment with 
mirtazapine. Your physician will monitor your health condition carefully 
during the treatment period, with regular assessments of your physical and 
mental state.
This study can present some other inconvenience: the participation in the 
study requires regular visits to a physician and each visit takes, at the 
average, more time than an ordinary visit to a physician. You will have to 
follow the dosing schedule very carefully and not to forget to return all 
unused tablets to your physician.
The expected benefit.
You can benefit from this study: the symptoms of your disease can 
improve or even disappear; you can experience improvement of memory, 
attention and information processing. In case you have had symptoms of 
depression or suffered from side-effects of your basic medicine, they may 
also improve or even disappear. It is possible that during the treatment with 
mirtazapine you will need a smaller dose of your basic medicine. Your health 
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condition will be monitored during the treatment very carefully and you will 
see your physician regularly. In addition, your participation in this study may 
help a large number of other patients for whom, supposedly, a new safe and 
effective method of treatment is being developed.
How to contact your physician.
If you experience any symptoms of worsening your health condition 
(physical or mental), you should contact your physician immediately, using 
the phone number that he or she will give you, or contact the physician on 
call 74-35-60. 
Additional information concerning the study.
Your participation in this study is completely voluntary. You have right to 
refuse from participation at any time during the study without any negative 
consequences for your treatment. In this case, you will be prescribed 
ordinary treatment. From the point of view of the study it is very important, 
however, that as a greater number of patients as possible will have completed 
the full course of treatment. If you decide to withdraw from the study 
anyway, it is desirable that you meet your physician for the final assessment 
as soon as possible.
The participation in the study is based on the principle of mutual 
confidence and your physician will guarantee you anonymity being strictly 
kept. This means that your name will be seen only in your medical record, as 
at any usual treatment. No information able to disclose your identify will be 
recorded in the study materials. In some special circumstances however, this 
information may be required by local, federal or international authorities 
monitoring the quality and ethical issues of clinical studies. An open and 
diligent cooperation between you and your physician is crucially important 
for the successful progress of the study.
Please feel free to ask any questions you may have, especially if there is a 
word or phrase you do not understand. After you have attentively read this 
information, you will be asked to sign THE INFORMED CONSENT FORM 
(see below).
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THE INFORMED CONSENT FORM.
I,   ________________________________________________, 
(surname, name, second name)
born  19 _____ 
have had enough time to learn the information concerning the study and 
the investigational medicine. I have full understanding of this information, I 
am aware of the study purpose, its duration and conditions of my 
participation in it. I am aware of the expected benefit from the treatment, as 
well as of its possible side-effects and potential risk for my health. I have 
received the answers to all the questions concerning my participation in the 
study.
With this statement I confirm my voluntary consent to participate in the 
study “Efficacy of add-on mirtazapine on the clinical and neuropsychologic 
parameters in schizophrenic patients treated with conventional 
antipsychotics – a double-blind placebo-controlled trial with an open-label 
extension phase”.
I have a right to withdraw from the study at any time.
«______»  _________________________ 200__ .
Physician 
_____________________________________________
(surname, name, second name)
Institution__________________________________________
(name)
The signature of the patient or his representative       ______________
The signature of the physician  ____________________________
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